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Hypoxic ischaemic encephalopathy affects 1.15 million neonates annually worldwide, 
the majority of whom are in low to middle income countries. It is the leading cause of 
death of term neonates in South Africa. 40% of infants survive with disability, which 
places a significant burden on family and state resources.  
The only effective therapy that reduces mortality and disability is therapeutic 
hypothermia, but its effect is limited with many still surviving with disability. 
Therapeutic hypothermia is now standard of care in high income countries, but is 
recommended with caution in resource-constricted countries. This is due to concerns 
about safety and whether a therapy tested in a different setting is directly applicable 
in these environments.  
Methods 
To address the safety and applicability concerns, we conducted a retrospective study 
to assess the feasibility and safety of therapeutic hypothermia after introducing it into 
routine care in our hospital. 
The second study documented the outcomes of infants treated after the introduction 
of therapeutic hypothermia. 
To assess whether the benefits of therapeutic hypothermia could be improved upon, 
the third study compared the outcomes of infants treated with therapeutic hypothermia 
only to those treated with therapeutic hypothermia plus morphine. 
The fourth study described the pharmacokinetic profile of morphine in serum and 
cerebrospinal fluid in the infants treated with therapeutic hypothermia plus morphine 
at a dose of 25 µg/kg/h for 72 hours.  
Results 
Study 1: we reviewed the management of 100 neonates treated with therapeutic 
hypothermia over 3 years. The majority could commence cooling within the 
therapeutic window of 6 hours, with a mean admission time of 4.9 hours. Rectal 
temperature was maintained within target range 83% of the time. Complications were 
transient and did not occur more frequently than in published trials. 
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Study 2: we documented the outcomes of 99 cooled infants. 17 infants died, 33 were 
lost to follow up. Of the 50 survivors that could be assessed at 1 year of age, 82% 
were normal and 18% had significant impairment. A severely abnormal aEEG 
background, severe HIE and an abnormal MRI were associated poor outcome. A good 
suck, mild HIE, primiparity and normal MRI were associated with good outcome. 
Study 3: 45 neonates were included in the randomised trial comparing therapeutic 
hypothermia with therapeutic hypothermia plus morphine. No significant differences 
were found in later outcome between the groups, but infants in the therapeutic 
hypothermia plus morphine group had less liver dysfunction and a lower seizure 
burden in the early clinical course. 
Study 4: morphine concentrations were measured at 24, 72 and 96 hours in serum; 
and at 72 hours in cerebrospinal fluid. Toxic concentrations were not found at the 
administered dose of morphine. There was no increased length of stay, need for 
ventilation or inotropic support as found in other studies. 
Conclusion 
Therapeutic hypothermia is feasible and safe in this setting. Survivors have good 
outcomes. Combining morphine with therapeutic hypothermia at 25 µg/kg/h is 






Hipoksiese isgemiese enkefalopatie(HIE) affekteer 1.15 miljoen neonate jaarliks 
wêreldwyd, die meerderheid van hulle is afkomstig van laer en middelinkomstelande. 
Dit is die hoofoorsaak van sterftes in voltermynbabas in Suid Afrika. 40% van hierdie 
babas oorleef met gestremdheid, wat ‘n betekenisvolle las op families en 
staatshulpbronne plaas. 
Die enigste effektiewe terapie wat mortaliteit en gestremdheid verminder is 
terapeutiese hipotermie. Die effek is egter beperk met baie wat steeds met 
gestremdheid oorleef. Terapeutiese hipotermie is nou standaardsorg in hoë-
inkomstelande, maar dit word met versigtigheid aanbeveel in lande met beperkte 
hulpbronne. Dit is weens besorgdheid oor veiligheid en die vraag of terapie wat in 
spesifieke omgewings getoets is direk toepasbaar is op omgewings met ander 
omstandighede. 
Metodes 
‘n Retrospektiewe studie is gedoen om die veiligheidsaspekte en lewensvatbaarheid 
van terapeutiese hipotermie te evalueer nadat dit ingestel is as deel van roetinesorg. 
Die tweede studie het die uitkomste van babas wat behandel is met terapeutiese 
hipotermie beskryf. 
‘n Derde studie is gedoen om te evalueer of die uitkomste in terapeutiese hipotermie 
verder verbeter kan word deur morfien by die behandeling te voeg. 
Die vierde studie beskryf die farmakologiese profiel van morfien in serum en 
serebrospinale vog in die babas wat behandel is met terapeutiese hipotermie plus 
morfiendosis van 25µg/kg/uur vir 72 uur. 
Resultate 
Studie 1: ons het die hantering van 100 neonate behandel met terapeutiese hipotermie 
oor ‘n 3 jaar periode hersien. Die meerderheid het afkoeling begin binne die 
terapeutiese vensterperiode van 6 uur, met ‘n mediaan toelatingstyd van 4,9 ure. 
Rektale temperature is gehandhaaf binne die teikenreikwydte 83% van die tyd. 
vi
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Komplikasies was tydelik en het nie meer gereeld gebeur as in gepubliseerde studies 
nie. 
Studie 2: ons het die uitkomste van 99 afgekoelde babas gedokumenteer. 17 babas 
het gesterf en 33 het nie opgevolg nie. Van die 50 oorlewendes wat teen 1 jaar 
geevalueer is was 82% normal en 18% het betekenisvolle inkorting gehad. ‘n Erg 
abnormale aEEG, erge HIE en ‘n abnormale MRI was geassosieer met swak 
uitkomste. ‘n Goeie suig, matige HIE, primipariteit en ‘n normale MRI was 
geassosieerd met ‘n goeie uitkoms. 
Studie 3: 45 babas is ingesluit in ‘n ewekansige studie wat terapeutiese hipotermie 
alleen vergelyk het met terapeutiese hipotermie plus morfien. Geen betekenisvolle 
verskille is gevind in die latere uitkomste tussen die groepe nie, maar babas in die 
terapeutiese hipotermie-plus-morfiengroep het minder lewerdisfunksie gehad asook 
‘n laer konvulsielading in die vroeë kliniese verloop. 
Studie 4: morfienkonsentrasies is gemeet in die serum teen 24,72 en 96 uur: en teen 
72 uur in die serebrospinale vog. Daar was geen toksiese vlakke met die toegediende 
dosisse nie. Daar was ook geen verlengde verblyf of toename in ventilasie of inotrope 
ondersteuning soos gevind in ander studies nie. 
Gevolgtrekking 
Terapeutiese hipotermie is uitvoerbaar en veilig in hierdie instelling. Oorlewendes het 
goeie uitkomstes. Die kombinasie van morfien met terapeutiese hipotermie word goed 
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Neonatal encephalopathy (NE) is the clinical syndrome of disordered neurological 
function, and hypoxic ischaemic encephalopathy (HIE) is NE that follows a perinatal 
hypoxic ischaemic event. Strict criteria for making this diagnosis are constantly being 
developed but the essential components are the development of encephalopathy in a 
term/near term neonate soon after birth following an intrapartum event likely to cause 
hypoxia-ischaemia(1). The incidence varies widely throughout the world and even 
within the same country can vary due to differing leves of care, and also due to different 
definitions(2,3). It remains the leading cause of term/near term neonatal deaths in 
successive reports on perinatal mortality in South Africa(4,5). In excess of 400 000 
infants survive with some degree of neurological impairment worldwide following NE 
(Figure 1), and the majority of them in middle income countries such as South 
Africa(6). In a study performed in our institution, perinatal insults accounted for 38% 
of cerebral palsy cases with hypoxia ischaemic encephalopathy a leading cause(7). 
Global burden of disease estimates in 2010 showed that intrapartum-related 
conditions result in 50 million disability adjusted life years (DALYs) and 6 million years 
lived with disability (YLDs)(6). These outcomes have major emotional and fincancial 
implications for families and health systems caring for children and adults with 
disabilities, and for the child’s prospects for academic and economic achievements. In 
low resource countries where even basic care is deficient, these outcomes have even 
more severe consequences. 
The clinical picture in HIE involves 3 stages of severity (stage 1-3 or mild, moderate 
and severe), which involve varying degrees of abnormalities in level of consciousness, 
tone, reflexes, autonomic function and seizures soon after birth. The original 
classification of HIE was described by Sarnat and Sarnat(8) and various simpler 
encephalopathy scores in use today are based on this classification. The outcome 
without treatment differs based on the severity of encephalopathy. Infants with mild 
HIE are expected to have a generally good outcome, approximately 25% of those with 
moderate HIE may have a poor outcome, and the majority of those with severe HIE 
will either die or survive with disability. 
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Figure 1: Intrapartum related death and disability outcomes in 2010(6) 
Pathophysiology 
It has been shown that the injury process following a hypoxic ischaemic insult evolves 
over time. After the initial insult there is usually some recovery of cerebral energy 
metabolism after resuscitation and reperfusion but this is followed, after a latent period 
lasting several hours, by a cascade of events that involves accumulation of excitatory 
neurotransmitters, reactive oxygen species, intracellular calcium and cytotoxic 
oedema, mitochondrial dysfunction and inflammation. This is the so-called period of 
secondary energy failure and results in ultimate neural cell death. It appears that the 
type of cell death may also differ in the different phases, with more necrotic cell death 
occurring in the acute phase or with severe insults and apoptotic cell death over a 
longer period of time(9). The phasic nature of changes in cerebral energy metabolism 
following hypoxic insult is demonstrated in brain MRS studies(10). 
It was then found, initially in animal studies, that mild to moderate hypothermia applied 
during the latent phase before the onset of the secondary injury phase and for a long 
enough duration preserves high energy phosphates and is neuroprotective(11). 
2
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Following on from the animal and pilot human studies confirming the safety and 
efficacy of therapeutic hypothermia (cooling) (12,13), several large international 
studies were performed to examine the effects of whole body cooling (14–17); or 
selective head cooling with mild systemic hypothermia (18) on outcome in neonates 
with hypoxic ischaemic encephalopathy (HIE). Their results showed that in infants with 
HIE, cooling is safe and if initiated timeously (within 6 hours of birth), reduces the 
likelihood of death and of severe handicap in survivors up to 18 months of age. 
Many systematic reviews and meta-analyses including large numbers of patients have 
subsequently confirmed the beneficial effects of cooling (19,20) and that both whole 
body and selective head cooling methods are equally efficacious (20). Importantly, 
they also showed increased survival with normal neurological function. These positive 
results have been shown to persist even into pre-school age (6-7 years) (21,22) and 
there is an association between favourable outcomes at 18 months and those at 
school-going age (7-8 years) (23). On the other hand, because the effects are quite 
modest, researchers have investigated whether altering the period of cooling or 
cooling to even lower temperatures might lead to even better outcomes. One such 
study was discontinued early after a futility analysis indicated a low likelihood of 
showing a significant benefit of longer and/or deeper cooling (24). 
Current recommendations from international regulatory organizations (25) suggest 
that cooling should now be part of standard care for infants with HIE, and should be 
offered in settings where intensive care facilities are available, following the strict 
protocols used in the cooling trials. They, however, still recommend caution in applying 
this therapy in low- and middle-income countries, where resources are limited and the 
safety profile has not been well-established. These regions also happen to be where 
the greatest burden of disease is experienced(6,26), and where neuroprotective 
therapies are most needed. 
In these settings, it is also important to be able to assess those infants that will (may) 
benefit from current and future neuroprotective therapies and to predict likely outcome 
in order to direct resources appropriately. Some of the tools that have been 
used/studied are described below. 
3
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Clinical and laboratory assessment 
Raised circulating nucleated red blood cells (NRBC) numbers have been reported in 
response to hypoxia.  They have been used to distinguish asphyxiated from non-
asphyxiated infants, to predict the development and severity of HIE, brain injury on 
MRI and neurodevelopmental outcome (27,28). This predictive ability has been 
confirmed even in infants undergoing TH (29). As this is a widely available test, it could 
be a useful tool for selecting patients for neuroprotective therapies where facilities for 
blood gas sampling are not available. 
An absolute requirement for receiving TH is the presence of moderate-severe 
encephalopathy. This can be assessed clinically or using neurophysiological tools 
such as amplitude integrated electroencephalogram (aEEG). 
Various clinical scoring tools have been developed to assess degree of 
encephalopathy in different settings. The most commonly used in Sub-Saharan Africa 
is the Thompson HIE score (30), which is a simple scoring system based on Sarnat 
(8) staging that was developed in the pre-cooling era, but has been shown to still be
useful both for selecting patients for therapy and for predicting those who will have a
poor outcome(31,32). This can be useful in settings where no other predictive tools
are available.
Neurophysiological assessment 
aEEG was used as part of the criteria for TH in at least 2 of the large cooling trials 
(14,18) . This was because it is an objective method of classifying encephalopathy, 
and early aEEG had a high predictive value for outcome prior to the cooling era (33). 
The predictive ability is shifted with hypothermia, but it still has many clinical 
applications. Outcome prediction is best at 36-48 hours with TH (34–36), and non-
recovery of background pattern at this point can assist with decisions about directing 
ongoing care. aEEG is also useful for diagnosing sub-clinical seizures, which can 
worsen outcome if untreated (37). 
The role of near infrared spectroscopy (NIRS) is not clear, but some studies have 




A study by Toets looking at the predictive ability of a combination of aEEG and NIRS 
in infants with HIE showed that aEEG had better predictive value, but NIRS did have 
some predictive ability. rSO2 and FTOE remained stable in those infants with normal 
outcome, but increased and decreased respectively after 24 hours in those with poor 
outcome. The increased rSO2 and decreased FTOE are thought to reflect increased 
cerebral oxygenation and reduced O2 utilisation consistent with secondary energy 
failure (38). Another study by Lemmers confirmed that the combination of aEEG and 
NIRS improved the predictive value of either on its own, and enabled prediction of 
outcome as early as 12 hours (39).  
Quantitative electroencepalogram (EEG) measures have demonstrated ability to 
distinguish between HIE grades(40), and once further developed and automated 
classification simplifies interpretation of neonatal EEG this may add to the arsenal of 
tools for selecting patients for treatments where available. 
It would therefore appear that a combination of neurophysiological tests may be more 
useful. A challenge for low income settings is the considerable cost of the equipment. 
Imaging 
The gold standard in neuroimaging for diagnosing type/timing of injury and predicting 
outcome is MRI (±MRS). However, this is not universally available and involves 
moving the ill infant to the site of the scanner. Cranial ultrasound (CUS) is a safe, more 
readily accessible method of imaging the neonatal brain but has always been 
considered to have a low predictive value for outcome.  However, with improvements 
in equipment and technique it is proving to be a very valuable tool with good predictive 
ability for more severe abnormalities(41).  
A low resistive index (≤0.55) on doppler ultrasound was previously associated with 
severe HIE and predicted poor outcome prior to the cooling era. With the introduction 
of TH many recent studies have shown that the predictive value of a low RI is altered 
and may be predictive before or after the cooling period (42,43). One study by Li et al 
found that even with TH, a very low RI of <0.46 on day 3 predicted poor outcome at 2 
years with 80% accuracy (44). 
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Recently, different groups have validated CUS as a predictive tool for use in settings 
where MRI not available. Annink et al developed and validated a CUS scoring system 
where they assigned a composite score accounting for different areas of the brain and 
specific signs, and correlated it with MRI scores, histological findings in those that died 
and outcome at 2 years of age. Scores on CUS performed in the first week after birth 
had good correlation with outcome. Correlation between CUS and MRI was moderate 
(0.67). Histological findings in those that died were consistent with CUS findings, but 
the damage was more extensive(45). 
Magnetic resonance imaging (MRI) and MRS in the first 2-3 weeks has been used 
both for timing injury, defining the extent of injury and for prognosis in infants with HIE. 
Most studies use scoring systems to describe the areas of the brain that are damaged, 
and the predictive value of MR imaging is preserved even with TH (46). MRI after TH 
could be used to predict outcome up to school-going age (47). A recent meta-analysis 
suggested that the best predictive value is obtained from MR imaging performed in 
the first week (<8 days) (36). 
Early post discharge assessment 
After the neonatal period, it is important to follow the infants up to assess the effects 
of treatments on neurodevelopment. In low resource settings where long term follow-
up is frequently challenging, it is even more critical to have tools that can be used early 
on to select those infants that require special attention and direct the limited resources 
accordingly. Assessment of general movements (GMs), which are part of the normal 
movement repertoire of infants up to approximately 5-6 months, has been shown to 
be highly predictive of later neurological development. Two specific types of 
movements have been associated with outcome. The character of fidgety type 
movements (FM) is particularly useful, with absent FMs having a sensitivity and 
specificity of 95% each for predicting cerebral palsy (48,49).  
Similarly, cramped synchronized movements at 1 and 3 months correlated very 
strongly with central gray matter abnormalities on early MRI and with motor outcome 
at 2 years in an Italian cohort (50). 
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The benefits of this method are its relative cost effectiveness. It requires a short video 
recording of the infants in the awake state, which can even be assessed remotely if 
there is no local expertise in GM interpretation. 
In summary, using a combination of tools that are feasible for the setting is likely to 
yield the best predictive power for later outcome (51). 
Rationale for study: 
Whilst there is animal evidence to suggest a synergistic effect of TH with some other 
agents there is currently minimal data showing whether, in the human neonate, 
combining therapeutic hypothermia with other neuroprotective strategies enhances 
the beneficial effects of cooling on outcome. Some ongoing/pilot studies are examining 
the effects of various combinations targeting the different pathophysiological 
mechanisms of injury (52,53). One of the agents that may potentially enhance the 
neuroprotective effects of cooling due to its immune modulating properties(54), but 
which has not been extensively studied in this respect, is morphine. There is evidence 
that morphine shares some properties with cytokines, which are the main immune 
modulators. Opioid receptors are expressed on immune cells and opiods modulate 
the immune response centrally and peripherally(55). 
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Neonatal encephalopathy or hypoxic ischaemic encephalopathy (HIE), which is 
neonatal encephalopathy associated with (presumed/documented) intra-partum 
events, continues to be a cause of significant neurological morbidity and mortality 
worldwide. The incidence has been reported as 1-8/1000 live births in some regions, 
to as high as 26/1000 in others (1). The true incidence is difficult to ascertain and 
varies widely due to a number of factors: improvements in antenatal and perinatal care 
in developed countries which have the lower incidence in contrast to severe resource 
and skills deficiencies in some developing settings; and differences in definition of HIE 
within and between studies(2). 
When infants present with neonatal encephalopathy, there is frequently debate about 
the exact nature and timing of the insult. There is conflicting evidence in the literature 
about whether the majority of insults occur in the antenatal or intrapartum period. 
Some studies indicate a predominance of antenatal factors contributing to NE(3,4); 
while more recent studies which included neuroimaging suggest that antenatal risk 
factors may be contributory, but intrapartum factors are the final requirement for 
development of HIE(5,6). This is significant, as more recent injury may be more 
amenable to neuroprotective therapies. 
Mechanisms of injury in HI 
Studies on animal models such as the 1-week old piglet model, relevant because of 
similar brain injury patterns to human newborns following hypoxia ischaemia, indicate 
a highly organized and topographic process of injury that targets regions of 
sensorimotor integration and control of movement(7).  
Glutamate receptor-mediated excitotoxicity plays a major role in brain damage in 
newborns after HI (Figure 2.1) (8,9). Glutamate is both critical to neuronal cell function 
and, in excess, toxic to those same cells. Glutamate binds to several receptors on 
neurons, including the N-methyl-D-aspartate (NMDA) receptors. Once released into 
the synaptic cleft, excess glutamate is removed via specific transporters found in 
astrocytes and astroglia and other neurons (10,11). 
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Altered glutamate handling and excess following cerebral ischaemia results in 
excitotoxicity characterized by alterations in intracellular ion concentrations, 
dysregulated protein phosphorylation via kinase activation and phosphatase 
inactivation, defects from energy depletion (adenosine triphosphate: ATP), 
mitochondrial failure, generation of reactive oxygen species, nitric oxide synthase 
(NOS) activation and prostaglandin synthesis(12,13).  There is some evidence 
showing that reactive oxygen species (ROS) contribute significantly to cell death in 
cerebral ischemia. ROS activate transcription factors, including nuclear factor kappa 
b which in turn activates cyclooxygenase 2, inducible nitric oxide synthase, adhesion 
molecules and inflammatory cytokines (14). ROS cause an increase in blood-brain-
barrier permeability, abnormal arteriolar reactivity, altered transport activity, enhanced 
neutrophil and platelet adhesion to endothelium, promote phospholipase A2 
activation, platelet activation factor production (PAF) and post-ischaemic 
hypoperfusion (15).  
Platelet-activating factor (PAF) is known to be elevated in the cerebrospinal fluid (CSF) 
of infants with hypoxic-ischemic encephalopathy and in rats, PAF is implicated in the 
progression of hypoxic-ischemic brain injury resulting from its stimulation of glutamate 
release(16,17).   
Several authors have described the central role played by the enzyme caspase 3, 
reactive oxygen and nitrogen species in hypoxic ischaemic injury(15,18). A significant 
mechanism of injury after secondary energy failure is accelerated and disordered 
apoptosis, which has been shown to be mediated by caspase 3 (Figure 2.2) (9). 
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Figure 2.1: Schematic diagram illustrating the different pathological phases of 
cerebral injury after severe hypoxic-ischemia(9). 
 
OFRs, oxygen free radicals; BBB, blood brain barrier; EAAs, excitatory amino acids; NO, nitric oxide. 
 
Figure 2.2: Flow chart depicting several intracellular mechanisms associated 
with permeabilization of the mitochondrial membranes, leading to progressive 
failure of mitochondrial oxidative phosphorylation and ultimately delayed 












AIF, apoptosis inducing factor. Apaf-1, apoptotic protease-activating factor−1; ATP, adenosine 
triphosphate; BAK, Bcl2-antagonist/killer 1; BAX, Bcl2-associated × protein; Bcl2, B-cell lymphoma 2 
protein family; Bcl-XL, B-cell lymphoma-extra-large; BID, BH3 interacting-domain death agonist; Diablo, 
direct inhibitor of apoptosis binding protein with low Pi; P53, p53 tumor suppressor protein; Smac, 
Second mitochondria-derived activator of caspase; tBID, truncated BH3 interacting-domain death 




Some of these described processes have been shown (mainly in animal studies) to 
be attenuated by whole body or head cooling. This is thought to work by modulating 
various processes such as glutamate release and oxidative stress, microglia activation 
and cytokine release, and normalizing protein synthesis(17,19). Other mechanisms by 
which hypothermia is thought to work are through reducing the loss of high 
energy phosphates(20), attenuating caspase-3 activation and hence apoptotic 
cell death(21), decreasing brain energy utilization and thereby maintaining ATP 
stores(22). 
Several clinical trials on human infants have been conducted in the last 20 years to 
assess the effect of TH, administered as selective head cooling with mild systemic 
hypothermia or as whole-body cooling, on outcomes of infants with HIE. The infants 
were recruited using strict entry criteria, cooled commencing within 6 hours of birth for 
a duration of 72 hours, and then re-warmed slowly. The results of these trials showed 
the efficacy of TH in reducing mortality and neurodevelopmental impairment at 18 
months, and even at school-going age. Some fairly recent meta-analyses involving 
1200-1300 infants recruited in the majority of these studies showed significant 
reductions in the composite outcome of death or disability in survivors (RR 0.75, 95% 
CI 0.68-0.83), with a number needed to treat  of 7 (23,24). There was similar efficacy 
of the two cooling methods, and no differences in multi-organ dysfunction and 
physiological effects of treatment (23). Following publication of these results, TH has 
been endorsed by regulatory organisations (25,26) and become standard of care in 
high income countries. 
Timing has consistently been shown to be critical when providing TH. While the 
original studies indicated that cooling had to be instituted within 6 hours in order to 
preserve brain tissue, both animal and human evidence shows that cooling is more 
effective the earlier after injury it is commenced (27–30), with better motor outcomes 
in human infants when cooled within 3 hours of birth (30). The therapeutic window 
appears to be inversely proportional to the severity of the hypoxic ischaemic insult; 
and Sabir et al showed that in rat pups with severe insult delayed cooling up to 12 
hours is even deleterious, resulting in greater brain injury than normothermia (29). In 
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human infants it appears that the current protocols of providing TH are the most 
suitable (optimal). Several different cooling strategies have been attempted without 
showing improved efficacy: starting cooling later (6-24 hours) and continuing for 96 
hours showed no clear benefit (31); while cooling for longer duration (120 hours) and 
to a lower temperature (32°C) was not shown to increase the benefits and might be 
associated with more adverse effects (32). It is therefore imperative to optimise current 
practice and find ways of rapidly transferring infants to treatment centres or even 
cooling in transport where feasible. This, however, should be offered in settings where 
appropriate equipment and monitoring is available and has to be balanced against the 
dangers of uncontrolled passive cooling. There is increasing evidence that even in 
well-resourced settings with experienced staff, passive cooling in transit results in 
many infants having sub-therapeutic temperatures on arrival at  the treatment centre 
and prolongs stabilisation time to target temperature (33–37). More efficient transport 
cooling is achieved with servo-controlled portable devices (38). This would also 
require less intensive monitoring by the transporting team, but this is currently limited 
by the cost of these devices.  
Optimising TH  
The beneficial effects of TH can be optimized by paying attention to certain parameters 
while providing treatment.  
Hyperthermia was shown in 3 of the cooling trials to be associated with increased 
likelihood of death and disability (39–41). It is therefore important to avoid 
hyperthermia before and after cooling. 
Low carbon dioxide levels affect cerebral blood flow and exacerbate brain injury, and 
have been associated with unfavourable outcomes in both the NICHD and CoolCap 
trials (39,42). Thus, it is essential to avoid hypocarbia, particularly in ventilated 
patients. 
Resuscitation after birth should be initiated without supplemental oxygen as hyperoxia 
has been linked with adverse outcomes and delayed cellular recovery in animal 
studies (43); whereas 21% O2 is associated with decreased encephalopathy, brain 
injury on MRI and mortality (44–46). 
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Glucose control is important as a post hoc analysis of the CoolCap study showed that 
both hypoglycaemia and hyperglycaemia are associated with adverse outcome in 
infants with HIE. This was independent of degree of encephalopathy or TH, and 
hypoglycaemia was worse than hyperglycaemia (47).  
Detection and management of seizures is another important aspect that requires 
attention. There is evidence that seizures in the presence of HIE are independently 
associated with additional brain injury and worse adverse outcomes (48,49). Seizure 
burden appears to be important, with total duration more than 40 minutes or more than 
13minutes/hour having the highest risk of abnormal outcome at 24-28 months (50). 
Other neuroprotection 
Because TH has relatively limited beneficial effect, with approximately 40-50% of 
treated infants still surviving with neurodevelopmental impairment, there is ongoing 
research effort to investigate the use of other neuroprotective therapies in combination 
with TH (Figure 2.3) (51). Several candidates have shown promise, particularly in pre-
clinical studies. 
Erythropoietin (EPO) has been shown to have antioxidant, anti-inflammatory, anti-
apoptotic and neurotropic properties; and pre-clinical trial showed improved outcomes 
in non-human primates after hypoxia ischaemia(45). In human neonates with HIE, 
multiple dose EPO in combination with TH was shown to be safe and to result in 
reduced brain injury on early MRI and improved motor outcomes at 1 year(52). 
Melatonin, which is an endogenous hormone that regulates circadian rhythms, has 
been shown to be a powerful antioxidant and anti-apoptotic agent at high doses. It 
was shown to be safe and resulted in reduced infarct size and improved neurological 
outcomes in pre-clinical models (53). 
Xenon, an anaesthetic gas with anti-apoptotic properties which showed promise in 
animal studies when combined with TH, conferred no additional benefit in human 
infants when added to TH for 24 hours and assessed using MRI and MRS (54). 
Stem cells were shown to improve histological injury and improve neurological 
outcome when used alone in animal models and it has been shown that it would be 
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feasible to administer them after birth to infants with HIE(55). However, combining 
stem cells with TH in a mice model resulted in worse outcomes than either therapy on 
its own (56,57). 
Allopurinol, a xanthine oxidase inhibitor with antioxidant and free radical scavenging 
activity, is another agent that is currently being studied for its neuroprotective 
properties. The large ALBINO trial will assess its effect on neurocognitive outcomes 
at 2 years when used in combination with TH after birth (58). It may also potentially be 
neuroprotective to the hypoxic foetus when administered to the pregnant mother (59). 
2-Iminobiotin, a vitamin B7 analogue which is a selective inhibitor of neuronal and
inducible nitric oxide synthase, was shown to be neuroprotective after perinatal
hypoxia-ischaemia in a pre-clinical model (60). It was found to be safe, inexpensive
and easy to administer in a study on newborns in a low income country (61).
These examples illustrate the need for further pre-clinical followed by large clinical 
trials before adjuvant therapies to TH can be introduced into clinical practice to define 
the optimal methods and timing of use (Table 2.1) (62). 
Figure 2.3: Model of damaging pathways and proposed mechanisms/times of 
action of different potential therapies(51) 
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Table 2.1: Summary of the evidence for additive neuroprotective effects with 
hypothermia and potential combination treatments(62). 
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HT x 12-24h 





P7 Yes (histology, 
MRI, functional) 







5.5h 15min HT x 72h 
Connexinhemichannel blockade 






3h 3h HT x 72h 
Cx43, connexin 43; EEG, electroencephalography; IGF-1, Insulin-like growth factor; MRI, magnetic resonance inaging; MRS, 
magnetic resonance spectroscopy; functional, neurobehavioral test. 
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Role of Morphine 
Morphine  
One of the cooling studies in HIE (41) whose findings confirmed the beneficial effects 
of cooling showed a greater treatment effect of therapeutic hypothermia than some of 
the other larger studies. It showed a 32% lower rate of the combined outcome of death 
or severe disability (OR 0.21) in the cooled infants, and importantly a 39% lower rate 
of severe disability in survivors. One explanation for this was the fact that all the infants 
in this particular study routinely received morphine as co-treatment.  
It is not clear why this hypothermia trial reported by the Neonatal Neuro Network Trial 
group showed better outcomes than other studies after cooling. The authors 
speculated that the administration of morphine, either as continuous infusion or 4-
hourly bolus dosages, averaging approximately 25µg/kg/h, may have contributed (G 
Simbruner, personal communication).  
It has previously been shown in animals that applying hypothermia without sedation 
may interfere with its neuroprotective effect, and this may be related to the stress of 
being cold and shivering(63). 
The ability of opioids to attenuate brain injury has been demonstrated by Angeles and 
colleagues, who showed significantly less brain injury on MRI, less alteration of brain 
metabolites on Proton MRS as well as better long-term neurological outcomes in 
infants with asphyxia when treated with opioids during the first week of life, despite 
being subjected to multiple painful procedures, including lumbar punctures, compared 
to controls(64). This group used higher doses of opiates (morphine: 30 – 40 µg/kg/min) 
than routinely used in clinical practice. Although it was a retrospective study and 
morphine or fentanyl was used, the authors showed that opioid therapy did not cause 
harm (apart from temporary requirement of ventilatory support) in asphyxiated term 
neonates exposed to repetitive tissue-damaging procedures in the first 2-4 days of life 
and suggested that it may provide a degree of neuroprotection.  
Short-term hypothermia has been shown to alter the metabolism of fentanyl in juvenile 
pigs(65). Roka and co-workers reported reduced morphine clearance and elevated 
serum morphine concentrations during moderate hypothermia and with infusion rates 
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exceeding 10µg/kg/h in comparison to normothermic infants(66). This group also did 
not describe any significant complications such as severe hypotension, although the 
hypothermia group did show a not statistically significant tendency to require a more 
extended period of ventilatory and cardiovascular support, and had a worse clinical 
encephalopathy score on day 4 of life. More recently, a secondary analysis of the 
MARBLE study(67) found that with pre-emptive morphine there was prolonged 
ventilation and hospital stay. This study showed neither increased neuroprotection, 
nor increased brain injury markers on MR spectroscopy or worse neurodevelopmental 
outcome in the morphine group.  The relevance of elevated concentrations of 
morphine and/or morphine metabolites (not measured in the study) remains 
undetermined. 
There is some evidence that morphine or opioids have an immuno-modulatory 
function (Table 2.2) (68–71), and it is known that inflammation plays a significant role 
in mediating injury following perinatal hypoxia-ischaemia(72).  
 A better understanding of the anti-inflammatory actions of opioids may result in 
important treatments for neuroinflammation secondary to perinatal hypoxic-ischaemic 
brain injury. Opioids act as modulators of neuronal cell death and survival and these 
effects appear to be independent of their analgesic properties(73). Morphine prevents 
peroxynitrite-induced apoptosis of primary astrocytes(74) and enhances proliferation 
of hippocampal progenitor neurons(75). Neuroinflammatory responses in astroglia, 
including chemokine expression (CXCL 10), are altered or down-regulated by opioids 
(Table 2.3) (68,76). While the mechanisms for the neuroprotective effect of morphine 
are incompletely understood, there is evidence to suggest that morphine attenuates 
oxidative and pro-inflammatory stress(77,78) suggesting that morphine may have an 
effect on neuroinflammation after a hypoxic-ischemic insult to the brain. Morphine 
treatment is associated with increased Erk expression and/or phosphorylation in 
neurons (79,80) and Erk is one messenger by which opioids transmit their 
neuroprotective effects.  
Morphine down-regulates phagocytic cell function, particularly of peripheral 
mononuclear cells and polymorph nuclear cells(81). Morphine attenuates leucocyte / 
endothelial interactions by influencing peripheral leucocyte rolling and sticking through 
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stimulation of endothelial-derived nitric oxide synthase(82). Exploring the immune 
suppressive effects of morphine and its possible role in enhancing perinatal 
transmission of the HIV, it was found that morphine up-regulates the shared opioid / 
beta chemokine CCR5 receptor expression on neonatal cord blood monocyte-derived 
macrophages and inhibits endogenous production of macrophage inflammatory 
protein-1 beta (MIP-1β)(70). In human fetal microglia and astrocyte cultures, 
chemokine genes are activated with distinct patterns. With regard to microglia, 
lipopolisaccharide (LPS) acts as a potent stimulant for MIP-1α and MIP-1β mRNA 
induction, but has no effect on chemokine induction for astrocytes (83).  Microglia are 
mobile, specialized macrophages capable of phagocytosis that support and protect 
neurons of the central nervous system and multiply when the brain is damaged. The 
bidirectional interactions between neuron and glia are important for maintaining 
normal neural activities and signaling mediators between these cell-types play a role 
in nerve regeneration. Microglia apparently migrate toward injured neuronal cell 
bodies to which they attach. Disturbance of this milieu through nerve cell injury results 
in CCR5 expression in microglia and subsequent expression of mRNA’s for the 
ligands: MIP-1α and MIP-1β and RANTES(83). As previously mentioned, morphine 
inhibits CCR5 ligand MIP1β expression and the question is how morphine at this level 
would affect nerve cell regeneration if it is taken into consideration that suppression of 
inflammatory mediators in microglia is by RANTES via CCR5 and that CCR5-deficient 
mouse brain shows accelerated cell death (84).   
The temporal relationship of expression of some cytokines such as interleukin-1beta 
(IL-1β), tumor necrosis factor-alpha (TNFα), and chemokines such as beta2-integrin 
and RANTES to that of immune cells led some authors to conclude that these 
molecules may have a role in the inflammatory response to insults in the immature 
central nervous system. Morphine was shown to suppress this response via activation 
of microglial p-opioid receptors(85). 
Although the interplay between morphine and systemic monocyte-derived 
macrophage receptor activity and brain glial cell receptor expression after hypoxia-
ischemia is likely to be complex, the possibility exists that morphine may play a role in 
decreasing the migration and flux of systemic inflammatory cells towards the region of 
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hypoxia-ischaemia as well as suppressing expression of pro-inflammatory 
chemokines such as MIP-1β, and affect RANTES (Table 2.4).  
Table 2.2: Effects of opioids on immune functions(68)_(summarised) 
Function Species 
Suppression of natural killer cell activity Mouse, rat, human in vivo 
Suppression of cellular responses to 
mitogens  
Mouse, rat, human ex vivo 
Depression of antibody production Mouse in vivo 
Depression of T cell mediated adaptive 
immune responses 
Mouse in vivo 
Depression of cellularity Mouse in vivo 
Induction of apoptosis Mouse in vivo, mouse in vitro, human in 
vitro 
Inhibition of cell growth Mouse in vivo, mouse in vitro, human in 
vitro, monkey in vivo 
Suppression of phagocytosis Mouse in vivo, mouse in vitro 
Down-regulation of cytokines and other 
inflammatory associated mediators 
Mouse in vivo, mouse in vitro, rats in 
vivo, human in vitro 
Table 2.3: Opioid effects on chemokine levels(68)_(summarized) 
Chemokine 
ligands 
Species Opioid Effect 
CCL2/MCP-1 Human in vivo 
Mouse in vitro 







CCL4/MIP-1β Human in vitro Morphine ↓ 
CCL5/RANTES Human in vitro 
Mouse in vitro 







CCL12/MCP-5 Mouse in vitro Morphine ↓ 
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CXCL1/IL-8/KC Human in vitro Morphine ↓ 
CXCL10/IP-10 Human in vitro Morphine, DAMGO ↑ 
Chemokine 
receptors 
   
CCR3 Human in vitro Morphine ↑ 
CCR5 Human in vitro Morphine, Methadone, 
DAMGO 
↑ 
CXCR4 Human in vitro Morphine, DAMGO ↑ 
DAMGO, a mu-opioid receptor selective agonist 
 
Table 2.4: Morphine/opioid effects at different levels 
 





↓ NK cells, lymphocytes, 







Opioid receptor expression 
by immune cells 




↓ antibody and cellular immune 
responses, NK cell activity, 






Increased Erk expression 
and/or phosphorylation in 
neurons and immune cells  
- main signalling    
pathways involved in 
mitogenic responses to 
external stimuli  
Increased neurogenesis/growth 






Neural-immune circuit with 
direct and indirect action 
on immune cells 
(Human and animal 
studies) 
↓NK cells, B cells, T cells, and 
phagocytic cells 
(polymorphonuclear leukocytes  
and mononuclear cells) when 





Direct ↓ effect on phagocytic 
cells in vitro 
Central Activation of microglial μ-
opioid receptors  
- effect blocked by 
naloxone and β-
funaltrexamine             
(general and MOR 
antagonists) 
Production of and migration 
towards RANTES (chemokine) 






b-chemokine alteration  Up-regulation of CCR5 receptor 
expression (coreceptor for HIV 
entry into macrophage),  
significant ↓ endogenous MIP-
1b  









NO anti-oxidant action Inhibition of Rotenone-induced 
oxidative cell death 
blocked IFNγ-induced 




dose-dependent  increase 
expression of ubiquitin (marker 




NK=natural killer. RANTES=regulated on activation, T cell expressed and secreted. MIP=macrophage 





For clinical interventions it is important to identify infants at risk for brain damage soon 
after birth, and within a therapeutic window. Cooling is considered to be most effective 
if instituted as early as possible within the six-hour therapeutic window after injury(30). 
Furthermore, there is a need to identify biomarkers of tissue injury that may assist in 
separating infants who would benefit from therapy from those who might be harmed 
by that same therapy(88). Some authors have suggested that it may ultimately be 
possible to use biomarkers to stratify infants undergoing TH into (i) those that are 
responding to treatment and have a good prognosis, (ii) those that are not responding 
and are at risk of surviving with neurodevelopmental impairment and (iii) those that 
are likely to die and hence need redirection or modification of further management 
accordingly(89,90). It is particularly important in resource-poor settings to have 
relatively simple tools for predicting outcome and for identifying those infants that 
might benefit from neuroprotective strategies.  
Many serum biomarkers of hypoxic ischaemic brain injury, such as protein S-100, 
neuron-specific enolase (NSE) and brain-specific creatine kinase (CK-BB), alanine 
aminotransferase (ALT) and aspartate aminotransferase (AST), have the limitations 
of non-specificity or temporal pattern of release, necessitating frequent sampling. 
Hence, they are more useful for differentiating asphyxiated from non-asphyxiated 
infants(91–93). In a systematic review, Ramaswamy and co-workers identified the 
biomarkers CSF neuron-specific enolase (NSE), CSF interleukin 1b and serum 
interleukin-1b and interleukin-6 as predictors of abnormal outcomes in survivors of 
encephalopathy after asphyxia or cerebral infarction. They suggested that these 
markers of outcome be studied prospectively to validate their usefulness(88). 
Another relatively simple marker of perinatal hypoxic injury that may be applicable 
even in resource-constrained settings is nucleated red blood cell counts (NRBC). 
These have been shown to increase to varying degrees following fetal hypoxia. In one 
study the number of NRBC in cord blood increased in response to both acute and 
chronic hypoxia, with the counts increasing to a greater degree after chronic hypoxia 
and with more severe encephalopathy(94). 
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This makes this test a promising candidate for selecting the most appropriate patients, 
even from remote areas (as this test is relatively widely available), that may benefit 
from neuroprotective treatment.  
Preliminary unpublished data from our cohort of infants with HIE treated with TH 
showed that increased NRBC within 6 hours of birth was associated with poor outcome 
(see addendum, chapter 8). This suggests that this simple blood marker could be 
further explored as a tool for selecting infants that may/may not benefit from 
neuroprotective therapies such as TH. 
Cooling in low resource settings 
While therapeutic hypothermia (cooling) has been established as standard of care for 
infants with moderate to severe hypoxic encephalopathy for at  least a decade in more 
developed (high income) countries(25,26), its use in less resourced settings is still 
somewhat controversial and limited by a number of factors. 
One of these has been a lingering uncertainty about whether it is directly applicable or 
safe in these settings and will not cause more harm. This concern was driven in large 
part by the results of a pilot study in Uganda where there was increased neurological 
morbidity and mortality in the therapeutic hypothermia group(95). Some of the 
postulated reasons for this lack of effect and even adverse outcomes were that there 
may be some underlying factors that make these populations different from those in 
which the original cooling studies were performed. These include maternal factors 
such as malnutrition; higher prevalence of complicated labour and infective processes 
that are often impossible to confirm due to unavailability of blood tests in many settings 
(96); the “natural cooling” phenomenon that may occur in more severely affected 
infants that may dilute the treatment effect. 
Notwithstanding the above concerns, the greatest need for neuroprotective therapies 
such as therapeutic hypothermia is in these low- and middle-income countries where 
the major burden of disease is, with 96% of newborns who developed intrapartum-
related neonatal encephalopathy in 2010 being born in the low resourced settings(97). 




• The infants may be too severely affected to benefit from therapy due to lack of 
skilled birth attendants and resuscitation facilities, or not being delivered at 
health facilities 
• The available tools for assessing and selecting infants for treatment, and for 
providing the treatment itself and monitoring, are often very costly and 
assessment requires expertise   
• The infrastructure needed (roads, ambulances, etc.) to ensure infants reach 
treatment centres within the required time frames/therapeutic window is 
frequently lacking. Patients sometimes have to find private transportation to get 
to hospital and pay for treatment, which further limits access. 
• Availability of intensive care facilities and adequate monitoring, which is an 
essential component of providing therapeutic hypothermia, is often limited. 
• Long term neurodevelopmental follow up is often challenging 
Some of these limitations can be mitigated by the use of simple tools, which have been 
validated and shown to be useful in clinical practice. The Thompson score is a clinical 
score for assessing the degree of encephalopathy based on Sarnat staging(98) that 
was originally developed in the pre-cooling era, and shown to be easy to implement 
and useful in predicting outcome at 1 year(99).  
In the cooling era, it has been re-validated and shown to be a still useful clinical tool. 
For selecting patients that could benefit from neuroprotection, Horn et al (SA) showed 
that a Thompson score of 7 or greater at 3-5 hours predicted an abnormal amplitude 
integrated EEG at 6 hours and moderate to severe encephalopathy within 72 hours of 
birth(100,101). Similarly, Biselele et al in the DRC showed that infants with scores of 
7-15 within 6 hours of birth were eligible for neuroprotective therapies and this could 
be used as a selection tool(102). 
For predicting short-term outcome, the Thompson score has been shown to still be a 
valid tool, with multiple studies showing that a high score predicts death or severe 
adverse outcomes even with therapeutic hypothermia. In separate studies Horn and 
Biselele showed a score of 16 or greater predicted death before discharge (101,102), 
while Thorsen et al showed a score of 12 or greater predicted death before discharge 
or severe seizures(103).  
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In order to assess the status of TH in LMIC, surveys have been conducted in some 
MIC: 
Joolay et al surveyed public and private neonatologists and paediatricians in South 
Africa in 2010 about their opinions and practices of TH. They found that 42% of 
respondents offered TH and  9% transferred to other centres for cooling. 24% did not 
offer, or plan to offer TH in near future. However, 98% of respondents felt that TH 
should be standard of care in tertiary units (104). 
Chandrasekaran et al conducted a similar survey of Indian neonatal units a few years 
later. They found a similar proportion of practitioners (51%) that offered TH as 
standard of care, 44% who wanted to but had no resources and 5% who wanted 
further rigorous evidence before starting. Many who did offer TH did so outside the 
established international protocols. 53% of them used locally improvised methods 
(105). 
Cooling devices 
It is evident that LMIC are not homogenous, and some areas are even less well-
resourced than others. To address the issue of expensive devices, many innovative 
methods of cooling have been or are being studied in low income settings to provide 
both SHC and WBC at low cost. These include frozen ice caps, frozen gel packs 
(FGP), water bottles, water cooling caps, servo-controlled fans, phase changing 
materials (PCM), laminar flow devices, clay pot cooling devices and even ambient 
temperature (106). Some of the challenges experienced with these methods have 
been excessive shivering, excessive temperature fluctuations and possible over-
cooling in absence of adequate nurse-to-patient ratios. Two studies that evaluated the 
PCM method in India found that it was safe and feasible, but was only effective in low 
ambient temperature (<28°C) and required intensive nursing monitoring to achieve 
target temperatures (107,108). When FGP were compared to PCM, there was a 
shorter induction time but even greater temperature fluctuations requiring more 
nursing input with FGP (109). The ideal cooling device in these settings is one that is 
servo-controlled but affordable, can run even without electricity, and requires minimal 
nursing input. Two such devices have been studied in LMIC countries and found to be 
effective, safe and relatively inexpensive: a laminar flow device in Brazil (110) and a 
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Tecotherm-HELIX device which is a simplified version of an existing device that was 
tested in India (111). Some unexpected findings in one of these feasibility trials were 
the high incidences of gastric bleeding, and significant tachycardia. These findings 
were not common in the studies from high income countries. These infants were also 
smaller, with mean birthweight 2900g. These highlighted the need for further study to 
understand the underlying pathophysiological processes and intrinsic factors that may 
be different in these populations, while offering TH in a safe controlled manner. 
A few studies, mostly using gel packs, looked at short term outcomes after TH in LMIC 
and found improvements in markers of oxidant stress, neurological state at discharge, 
mortality and developmental impairment at 6 months(112–114). A Brazilian study that 
did have longer term outcomes confirmed the utility of MRI for predicting outcome in 
developing countries (115). 
Several systematic reviews and meta-analyses have been conducted in the past few 
years in an attempt to answer the question of suitability of TH for low resource settings. 
Pauliah et al reviewed data involving 567 infants from 4 countries (116). They found 
that TH (both WBC and SHC) had no significant effect on mortality (RR 0.74; 95% CI 
0.44 to 1.25). They highlighted some factors that may have accounted for the apparent 
lack of treatment effect.  The majority (63%) of patients had mild-moderate HIE, most 
(88%) were not ventilated and few were sedated. The degree of NE may have diluted 
the treatment effect, and highlights the difficulties in assessing an evolving disease 
process particularly without access to objective assessment tools. Other contributing 
factors may have been patient-related such as obstructed labour, intrauterine growth 
restriction, maternal nutritional status, infections, and their response to treatment. 
However, concerns about the presumed higher prevalence of perinatal infection and 
that TH may not be as protective in inflammation-sensitised brains may prove not to 
be always warranted. Studies on Uganda (96) and India (112) showed a prevalence 
of <10% bacteraemia in encephalopathic neonates, which is similar to that shown in 
the studies from developed countries and would make TH not any less likely to be 
effective in LMIC countries. Environmental factors such as inadequate monitoring 
resulting in temperature fluctuations and excessive oxygen administration, inadequate 
sedation, lack of ventilation facilities, and possible inefficacy of the low technology 
devices used were also considered. They also could not report on outcomes as many 
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of the studies had no outcome data.  This again highlights the challenges of conducting 
studies in these settings, and MRI (where available) could play an important role in 
profiling the disease process as well as assessing the effects of neuroprotective 
therapies (117). Galvao et al in the same year performed a meta regression analysis 
involving 1889 infants in different settings, which included 662 infants in low resource 
settings. This study showed a significant reduction in mortality (RR = 0.77; 95% CI: 
0.65–0.92) with TH, which was not influenced by the GDP per capita of the setting 
where applied (118). 
Another systematic review and meta-analysis assessed the effects of low technology 
TH (LTTH) in settings where intensive care and ventilation facilities were available, 
and included 2 studies from LMIC (none from low income countries). They showed 
that LTTH had similar results to TH administered with high technology devices when 
applied in an intensive care environment (119). They suggested that LTTH should be 
offered as standard of care in low resource settings where high technology cooling 
equipment is not available, but facilities for ventilation and monitoring possible. 
Ethics/economics 
Other concerns about introducing TH to LMIC settings have been about converting 
high mortality into disability, which would be an even greater burden in low income 
settings. This concern has largely been dispelled in high income countries as data 
from cooling trials showed reductions in both mortality and disability in survivors, and 
there is at least some data showing similar findings in lower income settings albeit 
without longer term outcomes. Infants cooled in these settings also tended to have 
more moderate encephalopathy (116), and may thus derive the most benefit from 
being cooled. It is hoped that  a large ongoing RCT (HELIX) being conducted in 3 
LMIC (India, Bangladesh and Sri Lanka) that will enrol 408 infants will provide much 
of the required information about TH in LMIC. This study will have information on 
perinatal infection, gene expression, early MRI findings and long term outcome (120). 
The aims of the current work are therefore: 
• To document the safety and applicability of therapeutic hypothermia (cooling) 
in a middle-income setting, where facilities for monitoring and ventilation are 
32
Stellenbosch University https://scholar.sun.ac.za
available, and when applied within a strict protocol similar to the ones used in 
the clinical trials. 
• To document the early (1 year) outcomes of infants treated in this setting. 
• To determine the effects of combining cooling with morphine on outcome. 
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In this chapter, I discuss the methods used in conducting the study. 
Encephalopathy score 
A modification of the TOBY study entry criteria was used to select patients for 
therapeutic hypothermia (TH) in the initial cohort. The two main changes were: 
Amplitude integrated electroencephalography (aEEG) was not an essential criterion, 
and was used only when available. The other was the inclusion of the Thompson 
encephalopathy score of ≥10 in order to simplify the clinical assessment particularly 
at referring centres.  
This is a simple clinical scoring system based on the Sarnat and Sarnat classification 
of hypoxic ischaemic encephalopathy (HIE), that was developed in the pre-cooling era 
to enable the prediction (mainly in the developing world) of neurodevelopmental 
outcome at 1 year of age without the need for specialist paediatric/neurology training 
or expensive technology (1). It has only 9 clinical items that are scored (0-3) and the 
maximum score is 22. The peak score and duration of abnormality was highly 
predictive of outcome. The combination of a peak score of >15 and persisting 
abnormal score on day 7 had a high positive predictive value (PPV) of 92%, and a 
negative predictive value (NPV) of 100% for abnormal outcome at 1 year.  Infants who 
had a peak score less than 10 and were normal by day 7 had a normal outcome (see 
Figure 3.1). This was used to categorise infants into those at high risk and in need of 
close follow up, or those that could be discharged early from follow up. 
In the cooling era, it was re-validated and it was found that a Thompson HIE score of 
≥7 at 3-5 hours predicted an abnormal aEEG at 6 hours with a sensitivity and 
specificity of 90% and 92% respectively, and could be used to select infants for referral 
for neuroprotective treatments such as TH (2). 
Based on these findings, we adapted our criteria for TH and in the prospective RCT 




We also used the Thompson HIE score as originally used to monitor clinical condition 
daily, and classified encephalopathy grade based on the peak score in the first week: 
mild ≤ 10, moderate 11–14 and severe ≥15. We used this classification to calculate 
the predictive values of a high score ≥15 (indicating severe encephalopathy) for death 
or neurodevelopmental impairment at 1 year of age in the context of TH.  
In the prospective cohort, infants were classified according to initial HIE score prior to 
initiation of TH: moderate 7-14, severe ≥15. This was based on the findings by Horn 
et al that an early score of ≥7 predicted an abnormal 6 hour aEEG that would qualify 
infants for TH and moderate-severe encephalopathy within 72 hours with high 
accuracy (3). 
Figure 3.1: Thompson score trends in normal/abnormal outcome(1) 
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Amplitude integrated electroencephalography (aEEG)/neurophysiological 
monitoring 
Amplitude integrated electroencephalography (aEEG) is EEG that has been filtered, 
rectified, smoothed, compressed in time and is presented on a semi-logarithmic 
voltage scale. It was initially used to identify neonates at risk of brain injury and poor 
neurological outcome after birth asphyxia (4). It can be classified in two ways (see 
Figure 3.2 below):  
1. pattern recognition technique with 5 main background patterns
- Continuous normal voltage (CNV)
- Discontinuous normal voltage (DNV/DC)
- Burst suppressed
- Continuous low voltage (CLV)
- Flat trace/inactive (FT)
2. voltage criteria with 3 amplitude categories (5)
- normal: upper margin of band of aEEG activity >10 mV and the lower
margin >5 mV
- moderately abnormal: upper margin of band of aEEG activity >10 mV
and the lower margin <5 mV
- suppressed: upper margin of the band of aEEG activity <10 mV and
lower margin <5 mV, may be accompanied by bursts of high-voltage
activity (“burst suppression”)
Seizure activity is suspected when there is a sudden increase in voltage, together with 
narrowing of the band of electrical activity. This then confirmed by viewing the raw 
EEG that is recorded simultaneously. 
The advantages of aEEG are that it is more practical for use in the neonatal intensive 
care (NICU). It can be applied at any time of the day, without depending on availability 
of technicians. It provides continuous monitoring of trends of brain electrical activity. 
Neonatal staff can be skilled in application and interpretation with minimal training. 
The voltage classification system is easiest to teach/learn, and was found to have high 
inter-observer correlation (5). However, it preferable to use a combination of the 2 
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classification systems as the voltage may be altered artefactually by electrical 
interference such as electrocardiogram or ventilator equipment. 
Earlier monitors used one channel with bi-parietal electrodes that monitored general 
electrical activity and trends, but could not localize pathology. Newer models usually 
have 2 channels, allowing for monitoring of both hemispheres of the brain. 
In the study by Hellstrom-Westas, it was found that aEEG background pattern in the 
first 6 hours after birth predicted outcome at 18-24 months with 92% accuracy (4). This 
was useful as other tools such as US, CT or MRI only become predictive later on in 
neonatal course, and may not be helpful in selecting candidates for neuroprotective 
therapies that need to be instituted soon after birth. It was on this basis that abnormal 
aEEG formed part of the entry criteria of 2 of the large TH trials for HIE (6,7). 
In our unit, 2-3 aEEG devices were available (for 12 bed NICU & HC) at various times 
during the conduct of the studies, which meant that aEEG was not always available 
for all infants that required it. We did not discontinue monitoring of infants if the trace 
was still abnormal, but on occasion monitoring was discontinued before the end of TH 
if the trace was normal and equipment was needed for another infant.  
As discussed above, when available a 30-minute aEEG recording was used in our 
studies to support the diagnosis of moderate-severe encephalopathy, especially when 
there was some uncertainty about severity. aEEG patterns that were eligible for 
selection for TH were (Figure 3.2): discontinuous normal voltage (DNV), burst 
suppression (BS), continuous low voltage (CLV), and flat trace (FT) and any seizure 
activity. 
Once TH commenced, our infants were monitored continuously during the cooling and 
re-warming period where feasible, and occasionally for longer periods if aEEG 
remained abnormal. 
The recordings were assessed for duration of abnormal pattern, presence or timing of 
appearance of sleep wake cycling, symmetry, and presence of and burden of seizures. 
High seizure burden was defined as having >3 seizures/hour, or a single seizure 
lasting ≥30minutes. When there was suspicion of ongoing/sub-clinical seizures after 
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the period of continuous monitoring, formal EEG was performed in some infants. 
Recognition of seizures and in particular a high seizure burden was important in light 
of the reported association with additional brain injury in the setting of HIE, although 
this may be modulated to some extent by TH (8,9). 
Time taken to recovery of background pattern (in conjunction with other clinical 
parameters) was used to counsel parents about prognosis, and to make decisions 
about ongoing intensive care. Severely abnormal background (CLV/FT) persisting up 
to/beyond 48 hours was regarded as a poor prognostic sign(10,11).  






Cranial ultrasound (CUS) is the most frequently used, safe and accessible method of 
imaging the neonatal brain. It is mobile, relatively inexpensive, does not require 
movement of the ill infant and can be used in the NICU. In the context of neonatal 
encephalopathy (NE), it is used to screen for congenital abnormalities, for serial 
monitoring of brain pathology and to assist with prognostic information. Its limitations 
are that it is not as sensitive as MRI, certain areas of the brain are not easily visualized 
(convexities, posterior fossa), and some abnormalities (eg. white matter or 
myelination) may be subtle and easily missed. Quality of imaging is also influenced by 
the experience/skill of the sonographer, views obtained and equipment utilized.  
Common findings in HIE include(12,13): 
- diffuse increased echogenicity of the brain parenchyma, slit-like ventricles,
obliteration of the extracerebral fluid spaces and the interhemispheric fissure
(cerebral oedema)
- echogenicity in periventricular white matter
- echogenicity in the basal ganglia or thalami (may become prominent over time)
- cortical highlighting (injury to cortex and subcortical white matter)
- global brain injury  - deep grey matter, cortical grey matter and white matter
- haemorrhage – intraventricular, intraparenchymal, convexities
- low resistance index (RI)
Using improved scanning protocols, it has been demonstrated that CUS can be used 
in settings where MRI is not available/accessible (see Figure 3.3) and has reasonable 
predictive accuracy  (PPV 79-92%; NPV 79-96%) for outcome at 2 years of age (13). 
Major abnormalities on CUS have also been shown to predict neonatal mortality in a 
low resource setting (12).  
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Figure 3.3: Common ultrasound findings in HIE(13) 
 
a Moderate cerebral oedema (1 point), b severe cerebral oedema (2 points), c moderate periventricular white matter (1 point), d 
severe periventricular white matter (2 points), e moderate subcortical white matter (1 point), f severe subcortical white matter (2 
points), g moderate thalamus (1 point), h severe thalamus (2 points), i moderate putamen (1 point), j severe putamen (2 points), 
k “four-column sign” which means that both left and right thalamus and putamen are visible at the coronal view as four columns 
(1 point), l visibility of the PLIC (1 point).  
All infants had a minimum of one, and up to three, ultrasound scans during the NICU 
admission. The images were assessed by experienced neonatologists (2 reviewers in 
retrospective cohort; single reviewer in prospective cohort) using a local consensus 
classification. Timing of imaging was recorded and the following findings were 
documented:  
- presence of cysts within ventricles 
- cerebral oedema 
- abnormalities in basal ganglia and thalami (BGT), white matter (WM), cortex  
- intra-ventricular haemorrhage; 
- infarction  
- other abnormalities  
- the resistance index (RI) values on Doppler studies, if performed 




Magnetic resonance imaging (MRI) in the first weeks after birth is considered the gold 
standard for evaluation of the brain after hypoxic ischaemic injury. It is useful for 
assessing the timing, site and severity of injury, and MRI plus magnetic resonance 
spectroscopy (MRS) have been shown to be the best imaging predictors of long-term 
outcome. It can predict death and cerebral palsy; but also has the ability to provide 
quite specific information for carers regarding outcome, such as ability to walk or feed 
independently, likelihood of attending normal school, etc(14). 
Different classification systems (14,15) have been used to describe injury, which 
usually assess the following (Figures 3.4-3.7): 
- anatomical development
- evidence of subacute/established injury
- unusual patterns of injury
- abnormal signal intensities in: BGT, WM, posterior limb of internal capsule
(PLIC), cortex, brainstem, cerebellum
Fig 3.4: Scoring system for BGT injury 
Mild BGT Moderate BGT Severe BGT 
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Fig 3.5: Scoring system for the posterior limb of the internal capsule 
Normal SI in the PLIC Equivocal PLIC 
Asymmetrical and slightly 
reduced signal intensity in 
the PLIC 
Abnormal PLIC 
Absent signal intensity in the 
PLIC 
Fig 3.6: Scoring system for white matter injury 
Normal WM Mild WM Moderate WM Severe WM 
Fig 3.7: Scoring system for cortical injury 
Mild: 1-2 sites involved Moderate: 3 sites involved 
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The predictive ability of MRI was found to be preserved even in the context of TH, with 
moderate-severe abnormalities in the BGT, severe WM lesions, abnormal PLIC 
having a PPV of 84% for adverse outcome at 18 months (16). 
There are several limitations to the use of MRI for the indications listed above. A major 
challenge in most except the most well-resourced settings is limited access. In our 
setting, there is one scanner servicing a large tertiary hospital, which severely limited 
access for our infants. A further limitation was the requirement for imaging infants 
under general anaesthesia in our hospital. Another challenge of MRI is the need to 
move infants who may still be very ill to the scanner.  
In our studies, due to the limited access to the scanner, MR imaging could not be 
performed on all infants. In the retrospective cohort, infants were initially routinely 
referred for MR imaging if they had received TH and were imaged when a slot was 
available. This protocol was later changed, and infants were referred only if there was 
an atypical clinical history, severe cranial ultrasound abnormalities or suggestion of a 
congenital or metabolic disorder.  In the prospective cohort,  all infants were referred 
for imaging and aimed to be scanned within 3 weeks of birth. In both cohorts, there 
was a wide range of imaging times with some infants returning for scan after 
discharge.  Infants were imaged under general anaesthesia, which is routine at this 
hospital, and T1, T2 and diffusion weighted sequences were acquired. The MRI 
images were assessed by an experienced neuro-radiologist who was blinded to the 
early clinical course and later outcomes. The appearances of the BGT, posterior limb 
of the internal capsule, white matter, cortex and brainstem were recorded and 
classified as previously described (14).  
Neurological condition at discharge 
There have been studies showing that clinical neurological examination (which 
included assessment of tone, movement, reflexes, feeding ability) after the first week 
or at the time of discharge can be predictive of outcome (17,18).  They showed that 
abnormal findings were more predictive the later in the neonatal course the 
examination was done (Figure 3.8). A normal examination was predictive of normal 
outcome at any time. Time taken to establish feeding was found to be a useful marker. 
These findings could be useful in settings where no imaging or neurophysiological 
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tools for predicting outcome are available. The studies mentioned above, however, 
used detailed standardized neurological assessments which were not feasible in our 
setting. 
In our studies, we elected to evaluate 3 clinical parameters at the time of discharge 
and relate them to outcome: 
- having a good suck (feeding independently by cup or breast)
- being still encephalopathic (abnormal level of consciousness)
- abnormal tone
Figure 3.8: Normal and abnormal outcome in infants grouped according to the 
age at which the neurological examination was performed(17).  
Outcome assessment 
After discharge from hospital, infants in both cohorts were followed up at 3 months 
and 12 months, and up to 18 months in the prospective cohort. At these visits they 
had the following assessments: 
- a basic neurological examination with test positions and angles as described
by Amiel-Tison (19)
- the Bayley Scales of Infant and Toddler Development - Third Edition screening
test (Bayley-III Screening Test) in the retrospective cohort
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- the full Bayley Scales of Infant and Toddler Development -Third Edition (BSID-
III) in the prospective cohort
- hearing assessments using otoacoustic emissions (OAE) and automated
auditory brainstem responses (AABR) in the first three months
- visual reinforcement audiometry (VRA) at one year of age
The Amiel-Tison Neurologic Assessment at Term (ATNAT) was developed as a 
clinical neurological tool to examine neonates at term and shown to predict outcome 
(19). The test positions and angles described in the ATNAT are, however, frequently 
used in routine practice in follow up assessments of high risk infants even after the 
neonatal period, and enable detection of tone abnormalities. 
The Bayley-III Screening Test can be administered in a shorter time (15-25 minutes) 
to determine whether an infant is developing normally or whether further 
comprehensive testing is needed, and can therefore be used in routine clinical 
practice. Both developmental tests can be administered to infants from 1-42 months, 
and assess 5 domains of development: cognitive, expressive and receptive language, 
fine and gross motor function. Composite scores are then assigned for cognitive, 
language and motor development. Mean scores of 100 (±15) were considered normal, 
and scores <70 on any of the sub-scales were considered delayed, and those <85 
were considered at-risk. Although developed in children from a more developed 
setting, the BSID-III has recently been validated in a cohort of inner city South African 
children and found to be appropriate for use in this setting (20). 
Hearing impairment is reported frequently (9-10%) in infants with HIE treated with 
TH(21). Therefore, all infants are routinely screened for hearing loss. 
OAEs are used as a routine screening test for hearing loss in neonates. They assess 
cochlear/outer hair cell function, and can assist with confirming the type of hearing 
loss. 
AABRs are used to determine presence and type of hearing loss, and to estimate 
hearing levels for individual frequencies in each ear. They are used in newborns and 
infants who are incapable of providing accurate information for behavioural tests 
56
Stellenbosch University https://scholar.sun.ac.za
VRA is audiometry that has been adapted to assess hearing sensitivity in young 
children of 6 months to 3 years, where regular audiometry cannot be performed. The 
audiometer is reinforced with visual cues to allow the child to respond to sounds by 
turning the head. 
General movements (GMs) are part of the movement repertoire of normally 
developing young infants in the first 5-6 months. When evaluated in infants with HIE, 
it was found that absence of fidgety movements at 3 months had a high accuracy 
(87%) for prediciting outcome at 18 months (22); and presence of cramped 
synchronised movements at 1 and 3 months correlated very strongly with early MRI 
central gray matter abnormalities and with motor outcome (r = 0.83) at 2 years (23).  
At the 3 month visit, the infants in the prospective cohort had video recordings of their 
GMs made. Analysis of these recordings has not been completed. 
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Aim Therapeutic hypothermia (TH), shown in developed
countries to improve outcome in infants with hypoxic-
ischaemic encephalopathy (HIE), was introduced into
standard care at Tygerberg Children’s Hospital in 2008.
We aimed to describe the management and
characteristics of infants treated with TH at this tertiary
centre as well as the logistical challenges encountered.
Methods Infants admitted for TH between 2008 and
2011 were included. They fulfilled TOBY study entry
criteria and were cooled using a whole-body cooling
system. A retrospective analysis of the cooling process
and clinical findings was made using data collected
during treatment.
Results 100 infants with mild (32%), moderate (45%)
and severe (23%) HIE were treated over 3 years. Mean
time to admission was 4.87 (±1.63) hours, median time
from delivery to target temperature was 7.5 h (range
2.5–15.5 h). Mean temperature on admission was 35.5°
C (±1.5°C). Overall, rectal temperature was within target
temperature for 82.8% of the time. Complications noted
were clinically suspected/proven infection (45%),
abnormal coagulation tests (48%), thrombocytopenia
(34%), need for inotropic support (17%), hypoglycaemia
(4%) and hyperglycaemia (10%). Rate of follow-up at
1 year among survivors was 57%. Infants not attending
1-year follow-up were more likely to have HIV-infected
mothers, but there were no other demographic or clinical
differences when compared with those who attended
follow-up.
Conclusions Cooling is feasible in a resource-limited
setting, within a strict protocol. With close monitoring,
the known and common complications occur as
frequently as in less resource-limited settings. Surrogate
markers of later outcome need to be explored where
follow-up is problematic.
INTRODUCTION
Hypoxic-ischaemic encephalopathy (HIE) resulting
from perinatal asphyxia is the leading cause of
death in term-born infants in South Africa.1
Therapeutic hypothermia (TH) is the only treat-
ment that has been proven in multinational
studies2–6 to improve outcome in these infants.
In 2008, TH was introduced into standard care
at Tygerberg Children’s Hospital, a tertiary public
hospital with an eight-bedded neonatal intensive
care unit (NICU) and nurse:patient ratio of 1:2 or
1:3. However, most of the large studies showing
conclusive evidence of the benefits of TH in infants
with moderate or severe HIE have been carried out
in developed countries, with possibly different
populations and resources compared with our local
setting. There are few studies from emerging or
developing countries and those that have been pub-
lished had small study populations and/or used
varying low technology methods of cooling.7 8
One of these trials8 (done in a very low-resourced
region) had a high mortality rate in the cooled
group, which was of concern. It has been suggested
by different authors and regulatory organisations9 10
that cooling in these settings remains experimental
and should only be considered in intensive care
units under strictly controlled conditions.
Our aim therefore was to ascertain whether TH
was directly applicable and safe in our setting and
to document the complications and technical and
logistical issues encountered before and after initiat-
ing TH.
METHODS
Infants admitted consecutively to Tygerberg
Children’s Hospital (TCH) for TH between
November 2008 and November 2011 were
included. The selection criteria were based on the
TOBY study entry criteria.2 These included infants
of 36 weeks gestation or greater (assessed on the
best available of early ultrasound, Ballard score or
foot length (unpublished TCH data)) and with a
What is already known on this topic
▸ Therapeutic hypothermia for neonatal
hypoxic-ischaemic encephalopathy (HIE) has
been shown to be beneficial in reducing
mortality and later developmental impairment.
▸ The majority of studies showing this benefit
were done in developed countries.
▸ It is still a largely considered experimental
therapy in developing countries.
What this study adds
▸ Therapeutic hypothermia for neonatal HIE is
feasible in resource-limited settings within strict
protocols.
▸ Monitoring is essential as complications do
occur.
▸ Long-term follow-up is a challenge.
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birth weight of at least 1.8 kg. The infants needed to fulfil at least
one of the following: need for resuscitation for ≥10 min, Apgar
score ≤7 at 10 min, pH ≤7 or base deficit ≥16 on cord gas or
infant blood within an hour of birth. In addition they had to
have seizures or moderate to severe encephalopathy on clinical
grounds, or a Thompson HIE score of at least 10.11 Where
amplitude-integrated electroencephalogram (aEEG) was available
and time permitted, a short 30 min recording was used to
confirm the presence of moderate or severe encephalopathy.
Infants received whole body cooling for 72 h to a rectal tem-
perature of 33°C –34°C, using the Tecotherm TSmed 200 N
system. A retrospective analysis, with ethical approval from
Stellenbosch University Human Research Ethics Committee
(N10/05/157), of the cooling process and clinical findings
during cooling was made using information from contemporan-
eous data collection proformas and from medical notes.
RESULTS
One hundred infants were treated with TH over 3 years.
Perinatal characteristics of this cohort are summarised in table 1.
Classified using the Thompson score,11 32% had mild, 45%
moderate and 23% severe HIE; four infants were not classified
because of insufficient records (table 2).
Eleven infants died in the neonatal period before discharge.
Cooling process
Mean time to admission to NICU was 4.87±1.63 h (median 5,
range 1.5–8.5 h); median time from delivery to target tempera-
ture was 7.5 h (range 2.5–15.5 h) (figure 1). Twenty-two infants
were older than 6 h, and 8 older than 6.5 h at admission. Eight
of the infants admitted after 6 h were born at the cooling
centre.
Mean temperature on admission was 35.5±1.5°C (figure 2).
Five infants had very low temperatures on admission: 29°C in
one and 32°C in four. In four infants, the temperature on
admission was high: 38°C in two and 39°C in two.
Average time within the target temperature range was 19.3
±3.5 h on day 1, 19±3.7 h on day 2 and 21.4±3.5 h on day 3
(figure 3). Overall, rectal temperature was within target tem-
perature for 82.8% of the time.
Additional clinical findings
Forty-five per cent of the infants were treated for clinically sus-
pected infection; blood and/or cerebrospinal fluid culture was
positive in 8% (table 2). Coagulation test results were abnormal
in 48% (14% required treatment), and 34% had thrombocyto-
penia. None had a clinically significant bleeding disorder.
Seventeen per cent received inotropes for blood pressure
support. There was no difference in complications between
HIV-exposed and HIV-unexposed infants.
Other neonatal complications were transient renal (14%) and
liver (18%) dysfunction, hypoglycaemia (three infants) and




Eleven infants died in the neonatal period; 10 were considered
to be so severely affected that care was redirected with with-
drawal of intensive care and in five, care was redirected before
cooling was completed. These decisions were based on a com-
bination of HIE scores,11 severe aEEG abnormalities and cranial
ultrasound findings known to be associated with poor outcome.
The eleventh patient died from Acinetobacter sepsis.
Long term
There was a large attrition bias with 37 infants lost to follow-up,
resulting in longer-term outcome data available for 52 infants
only.
Three infants died after the neonatal period and two of them
from causes unrelated to asphyxia—one from an AIDS-related
illness, one from gastroenteritis. The third infant’s cause of
death is uncertain.
Neurodevelopmental assessments between 5 and 12 months of
age (median age: 12 months) were available for the remaining 49
infants. Forty-three (87.7%) were normal, or had minor abnor-
malities including speech and hearing impediments. Six were
severely abnormal when assessed at a median age of 12 (range
12–13) months. 10 infants with initial minor abnormalities had
persisting abnormalities when reassessed at 15–32 months. Four
Table 1 Perinatal characteristics
N=100
Maternal characteristics
Maternal age, median (range), years 23.5 (15–46)
Primiparity, n (%) 58/93 (62.3)
HIV positive, n (%) 19/89 (21.3)
Infant characteristics
Male, n (%) 59 (59)
Inborn, n (%) 33 (33)
Gestational age, median (range), weeks 39 (35–43)
Birth weight, median (range), grams 3060 (1960–5190)
Emergency Caesarean section, n (%) 21/98 (21.4)
Sentinel event, n (%) (UR, abruption, cord prolapse,
acute exsanguination)
8/98 (8.1)
Shoulder dystocia, n (%) 5/98 (5.1)
Apgar at 1 min, median (range) 2 (0–6)
Apgar at 5 min, median (range) 4.5 (0–8)
Apgar at 10 min, median (range) 6 (1–10)
Apgar at 5 min <5, n (%) 47/97 (48.5)
pH within the first hour, mean±SD 7.03±0.15
pH within the first hour, median (range) 7.02 (6.61–7.4)
pH within the first hour <7.00, n (%) 35/81 (43)
UR, uterine rupture.
Table 2 Clinical course and short-term outcomes
n (%)
HIE score*
Grade 1 31/96 (32.3)
Grade 2 43/96 (44.7)
Grade 3 22/96 (22.9)
Abnormal coagulation 37/77 (48.1)
Thrombocytopenia 26/77 (33.8)
Inotropic support 13/77 (16.9)
Suspected and confirmed infection 45 (45)
Time to full oral feeds (days)
Mean (SD) 7.58 (±3.47)
Median (range) 7 (3–18)
Strong suck at discharge 49/66 (74.2)
Abnormal neurology at discharge 11/68 (16.2)
Neonatal deaths 11 (11)
*Thompson et al.11 HIE 1: ≤10, HIE 2: 11–14, HIE 3: ≥15.
HIE, hypoxic-ischaemic encephalopathy.
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had speech delay (18–32 months), three had developmental
delay (18–20 months), one had mild fine motor delay
(23 months) and two had autistic features (18 months). One
infant with aqueduct stenosis died postoperatively at 15 months.
Two of these 10 infants with further follow-up were HIV
exposed: one had developmental delay at 18 months and the
other had speech and mild fine motor delay at 23 months of age.
More inborn than outborn infants (50% vs 23.3%; p=0.045)
had a poor outcome.
Of the five infants with excessively low admission tempera-
tures, two were normal at 1 year, one died and two had
unknown outcomes (including one with a temperature of 29°C
and one with a normal MRI at 3 months).
Three of the four infants (75%) with high temperatures on
admission had poor outcome: two died, one has cerebral palsy;
the remaining infant’s outcome is unknown.
Of the 22 infants cooled after 6 h, 10 had good outcome, 8
had poor outcome (6 died, 2 have severe cerebral palsy), and in 4
the outcome was unknown. There was no significantly increased
proportion of infants cooled after 6 h in the group with poor
outcome (8/20, 40%) compared with the group with favourable
outcome (10/43, 23.3%; p=0.232). There was also no difference
in poor outcome between inborn (3/20, 15%) and outborn
infants (5/20, 25%; p=1.000) in those cooled after 6 h.
Apart from a greater proportion of HIV exposure among
infants who did not attend follow-up (24.3% vs 15.9%,
p=0.003), there were no significant differences in perinatal
characteristics, early clinical picture (encephalopathy grade,
aEEG and cranial ultrasound doppler abnormalities, and com-
plications) and neurological condition and ability to feed at dis-
charge, between the infants with known outcomes and those
lost to follow-up (see online supplementary table). In those who
were scanned (routine MRI was only available until April 2011),
there were also no significant differences in the rate of abnormal
MRI findings (19.2% vs 20% in known vs unknown outcome,
p=1.000).
DISCUSSION
This is the first large study to report on the practical application
of TH in a developing world setting that also has information
on long-term follow-up. We have found many similarities to the
findings of studies from developed countries and also some
Figure 1 Times to admission and target temperature.
Figure 2 Temperature on admission.
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factors that are unique to this type of setting. Our findings that
the majority (77%) of cooled infants had mild or moderate
encephalopathy (mild 32%, moderate 45%—table 2) are similar
to those from a meta-analysis of cooling in low-income and
middle-income countries.12 This may be a reflection of the evo-
lution of the disease in these populations or may indicate a need
for more rigorous application of cooling criteria particularly
where aEEG is not routinely used for selecting patients. The
fact that two infants of 35 weeks gestation were cooled despite
the criteria stipulating a gestation of ≥36 weeks suggests that the
latter is more likely. However, this may also be related to estima-
tion of gestational age by Ballard scoring, which may not be
accurate, and clinicians’ inclination to give them the benefit of
doubt. In contrast to developed country settings,13 there were
also fewer ventilated patients and a greater proportion treated
for infection. The low number of ventilated patients was despite
cooling being applied in an NICU setting with ventilation facil-
ities and is therefore a true reflection of the infants’ degree of
illness and not of resource limitations.
Effort was made to get infants to the cooling centre within
6 h of birth in order to start TH. However, since there is a
limited dedicated neonatal transport service in the region and a
wide geographical drainage area, cooling was still offered if the
infants were received within 8 h. This decision was based on
one animal study14 showing effectiveness of cooling, although
diminished with increasing time, up to 8.5 h after injury. After
noting that it was largely possible to commence cooling within
the recommended time in this population, the 6 h cut-off was
enforced more strictly. The observed 4.87 h to commencement
of cooling was similar to the 4.5 h noted in international
studies.15 The minimum time to commence cooling was 1.5 h.
More importantly, 15 infants had reached the target tempera-
ture range by 6 h and 5 of them in 4 h or less. This is relevant
because there was a trend towards better outcomes in infants
cooled within 4 h of birth in one of the large cooling studies.16
Although there was no significant difference in outcome
between inborn and outborn infants in those cooled after 6 h,
this however did not take into account the four infants with no
outcome data. Of great concern were the eight infants born in
the cooling centre who commenced cooling after 6 h. This was
likely due to delayed recognition of the infants’ clinical condi-
tion and indications for cooling and illustrates the need for
ongoing education.
Local ambulance services are not equipped with rectal probes
or low reading thermometers, and staff are not trained to
monitor and respond to changes in cooled infant temperatures
appropriately during transit. Hence, the advice given to refer-
ring units and transport services is to maintain the infants’ skin
temperature at 36°C until arrival at the cooling centre. The
average admission temperature of 35.5°C was similar to that
found in the neo.nEuro.network Trial.6 Fifty-five per cent of the
infants had a temperature below 36°C on arrival, and alarmingly
5% had very low temperature of 32°C or less. This could be
due to referring units’ enthusiasm to start cooling within the
therapeutic window, or a reflection of the illness severity, as it
has been shown that severely encephalopathic infants have a
greater propensity to drop their temperatures.17 It does,
however, highlight the dangers of uncontrolled cooling during
transport. Although there have been some studies showing no
changes in physiological data or increases in complications in
infants cooled to temperatures as low as 31°C–32°C,16 18 other
authors do caution about the dangers of excessive cooling even
if being monitored.17 19 There is also concern that the usual
response to overcooling is to rewarm the infant to target range
resulting in fluctuating brain temperatures, the implications of
which are unknown and might actually compromise the protect-
ive effects of hypothermia. In this cohort, of the five infants
with excessively low admission temperatures two were normal
at 1 year, one died and two had unknown outcomes (including
one with a temperature of 29°C and one with a temperature of
32.4°C who had a normal brain MRI at 3 months).
It has been shown in the large hypothermia trials3 5 6 that tem-
peratures of ≥38°C are associated with unfavourable outcomes.
In this cohort, 75% (3/4) of the infants with very high tempera-
tures on admission had a poor outcome: two died, one has cere-
bral palsy, and the remaining infant’s outcome is unknown.
Once cooling was started, the overall maintenance of tem-
perature within target range of 83% was not significantly differ-
ent from the 81% previously reported in other settings using a
similar cooling method.20 The same study demonstrated that
manually-controlled cooling systems are associated with greater
temperature variations when compared with servo-controlled
systems. These variations, particularly in the initiation phase of
cooling and the time taken to reach target temperature
(figure 1), were noted in the current study and are likely to be
increased in a setting where there is inadequate staffing.
The majority of laboratory abnormalities and complications
were transient and recovered after the cooling period, as
described in the literature,21 22 except in four infants with other
complications such as necrotising enterocolitis (NEC) and septi-
caemia. One infant developed NEC and had thrombocytopenia
and coagulation abnormalities after the cooling period. Three
Figure 3 Hours within and outside
target temperature range.
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other infants had abnormal platelet and coagulation studies
associated with infection, one of whom started during cooling
and subsequently died after withdrawal of care due to severe
infection on day 6. Importantly, there was no significantly
increased proportion of infants with infection in those with
poor outcome.
The role of HIV exposure was a concern in this setting with
a high HIV prevalence. Mothers and infants would have been
on the current national Prevention of Mother-to-Child
Transmission (PMTCT) programme (which changed during the
study period), depending on when they presented for care and
mother’s disease stage. We found more HIV-exposed infants in
the group lost to follow-up; however, information on maternal
and infant treatment was not systematically collected in this
study. This is a limitation as this information might have given
some indication of whether infants at higher risk of perinatal
transmission (no or inadequate prophylaxis) had a different clin-
ical presentation, complications such as NEC, and outcome. An
association has been reported between NEC and maternal HIV
infection and antiretroviral drugs.23 24 Despite this, we were
able to ascertain that apart from younger maternal age and
more primiparous mothers in the unexposed group, there were
no significant differences between HIV-exposed and HIV-
unexposed infants regarding perinatal characteristics, severity of
illness, complications and MRI abnormalities. The one infant
diagnosed with NEC was not exposed to HIV.
CONCLUSIONS
This study has shown that it is feasible to apply TH safely in
resource-limited conditions, using similar technology and proto-
cols to those used in the large published trials. It is also safe in a
population with high HIV exposure and often poor availability
of antenatal information. However, it should only be applied
where adequate monitoring and support are possible as the well-
described complications of cooling do occur, although not more
commonly than in published trials. The extreme temperature
fluctuations before and in the early phase of cooling are con-
cerning, and suggest that automated systems of cooling might be
more suited to this environment, to ensure better maintenance
of temperatures within target range, but cost is a limiting factor.
There is a need for ongoing training in order to ensure early rec-
ognition and correct assessment and management of infants with
HIE who will benefit from early cooling. This training needs to
ultimately include referring, transport and treating teams.
Where follow-up is problematic, surrogate markers of
outcome such as neurological examination at discharge should
be explored.
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ABSTRACT
Aim: This South African study documented the survival and neurodevelopmental
outcomes of infants with hypoxic-ischaemic encephalopathy (HIE) after introducing cooling
to a neonatal intensive care unit and identified early markers for neurodevelopmental
outcome.
Methods: We retrospectively reviewed infants that received cooling according to the Total
Body Hypothermia trial protocol from 2008 to 2011. Infants were screened with the Bayley
Scales of Infant and Toddler Development, Third Edition, at one year of age and underwent
neurological and hearing assessments.
Results: Data on 99 infants with HIE showed that 45% of cases were moderate, 23%
severe and 32% mild. An abnormal amplitude integrated electro-encephalogram (aEEG)
background was documented in 45 cases within 24 hours. Magnetic resonance imaging
(MRI) scans were consistent with HIE in all but one case. We reviewed 50 traceable
survivors at one year. Development was significantly impaired in nine and 41 were normal
or mildly impaired. A severely abnormal aEEG background, severe HIE and an abnormal
MRI were associated with death and severe impairment. A good suck, mild HIE, primiparity
and normal MRI were associated with good outcomes.
Conclusion: Most infants with HIE survived without major impairment. Previously
described predictors of neurodevelopmental outcome were good surrogate markers in this
population.
INTRODUCTION
Birth asphyxia results in significantmorbidity and is the third
most common (23%) global cause of death in the neonatal
period (1). Although it has not been well documented in sub-
Saharan Africa, two studies (2,3) reported an incidence of
hypoxic-ischaemic encephalopathy (HIE) resulting from
birth asphyxia that ranged between 3.8 and 8.3 per 1000 live
births in two different regions in South Africa.
Therapeutic hypothermia (TH) to treat HIE infants was
introduced into standard care at Tygerberg Children’s
Hospital in Cape Town, South Africa, in 2008 following
the publication of positive results from international studies
(4,5). Although there were concerns about safety and
applicability arising from small studies using low technology
methods from developing countries (6,7), we recently
demonstrated that it is feasible and safe to apply TH in
resource-limited settings using similar technology and pro-
tocols as in developed countries, provided there is adequate
monitoring and support. In our cohort of 100 neonates
Abbreviations
aEEG, Amplitude integrated electro-encephalogram; BGT, Basal
ganglia thalami; EEG, Electro-encephalogram; HIE, Hypoxic-
ischaemic encephalopathy; HIV, Human immunodeficiency
virus; MRI, Magnetic resonance imaging; NICU, Neonatal
intensive care unit; NPV, Negative predictive value; PPV, Positive
predictive value; TH, Therapeutic hypothermia; TOBY, Total
body hypothermia trial.
Key notes
 This South African study documented the survival and
neurodevelopmental outcomes of 99 infants with
hypoxic-ischaemic encephalopathy (HIE) after introduc-
ing cooling to a neonatal intensive care unit.
 Many infants survived without major impairment.
 Severe hypoxic-ischaemic encephalopathy, severe
amplitude integrated electro-encephalogram back-
ground and abnormal magnetic resonance imaging
(MRI) findings were associated with poor outcome,
while mild HIE, primiparity, good suck at discharge and
normal MRI were associated with favourable outcome.
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treated over a three-year period, complications from cooling
occurred at a similar rate as in published trials (8).
This study aimed to document the clinical course and
outcomes of infants treated with TH at Tygerberg Children’s
Hospital and to assess which neurological investigations
could be used as surrogate markers for neurodevelopmental
outcomes at one year of age.
METHODS
Setting
Tygerberg Children’s Hospital is a tertiary public referral
hospital in Cape Town, South Africa, with 124 neonatal
beds and 6103 annual deliveries. It serves the eastern
metropolitan region of Cape Town, as well as a large rural
Western Cape catchment area with 46 150 annual deliver-
ies in 2011.
Patient selection and management
We included all infants admitted for therapeutic hypother-
mia to the neonatal intensive care unit (NICU), from
Tygerberg Children’s Hospital and its referring centres,
between November 2008 and November 2011. These
infants constituted 8.2% of total NICU admissions for the
study period. Their suitability for TH was determined
according to the Total Body Hypothermia (TOBY) study-
based criteria (9): a gestational age of ≥36 weeks and birth
weight ≥1.8 kg; the need for resuscitation for ≥10 minutes
and, or, an Apgar score ≤7 at 10 minutes and, or, a pH of ≤7
or base deficit ≥16 on cord gas or infant blood within an
hour of birth. In addition, these clinical features had to be
present: seizures or moderate to severe encephalopathy or a
Thompson score ≥10 (10).
Infants were cooled for 72 hours to a rectal temperature
of 33–34°C using the Tecotherm TSmed 200 N (Inspiration
Healthcare Ltd, Leicestershire, UK) whole-body system.
All infants had cranial ultrasound imaging performed at
least once during their NICU admission and had amplitude
integrated electro-encephalogram (aEEG) monitoring
where available during cooling, using the single channel
Olympic CFM 6000 (Natus Medical Incorporated, San
Carlos, CA, USA) or 2-channel Brainz BRM2 (Natus
Medical Incorporated) devices. Some infants had full
electro-encephalogram (EEG) examinations, at the attend-
ing clinicians’ discretion.
Between November 2008 and April 2011, all cooled
infants were routinely referred for magnetic resonance
imaging (MRI) and were imaged when a slot was available.
After this time, due to limited access to the scanner, infants
were only referred for anMRI if there was an atypical clinical
history, severe cranial ultrasound abnormalities or sugges-
tion of a congenital or metabolic disorder. All infants were
imaged under general anaesthesia, which was a routine
practice at the hospital, using a Siemens Magnetom Sym-
phony 1.5 Tesla magnet (Siemens Healthcare, Erlangen,
Germany) with T1, T2 and diffusion weighted sequences.
Neurodevelopmental assessments were performed at
three months and at one year by an experienced develop-
mental paediatrician using the Bayley Scales of Infant and
Toddler Development, Third Edition screening test (Bayley-
III) and a basic neurological examination that included the
test positions and angles described by Amiel-Tison (11). We
also performed hearing assessments, in the form of oto-
acoustic emissions and automated auditory brainstem
responses within the first three months and visual rein-
forcement audiometry at one year. Non-attending care-
givers were contacted by telephone and asked whether the
child was still alive and if the infant had died this was
included in the results.
Data collection and analysis
Clinical information was collated from contemporaneous
data collection proformas and medical notes. The infant’s
HIE severity was classified based on the peak Thompson
score in the first week: mild ≤ 10, moderate 11–14
and severe ≥15 (10). Cranial ultrasound and aEEG
recordings were individually reviewed by two experienced
neonatologists.
Cranial ultrasound images were assessed using a consen-
sus classification system for: day imaged; evidence of cysts
within ventricles (sub-ependymal, choroid plexus); cerebral
oedema; abnormalities in basal ganglia and thalami (BGT),
white matter, cortex; intra-ventricular haemorrhage; infarc-
tion and other abnormalities. The results of Doppler studies,
if performed, and the value of the resistance index were
documented.
The aEEG recordings were reviewed using a pre-agreed
combination of voltage and pattern recognition classifica-
tions. Recordings were divided into 12-hour time periods
and analysed for predominant background pattern, pres-
ence of normal sleep–wake cycling as well as the presence
and burden of seizure activity. High seizure burden was
ascribed when there were more than three seizures within
an hour or a single seizure lasted more than 30 minutes.
The number of hours it took to recover from abnormal
backgroundpatternswerenoted,aswellasthetimetodevelop
sleep–wake cycling and the total duration of recordings.
Poor quality data that could not be fully interpreted were
excluded from further analysis. EEG recordings were
analysed and reported by paediatric neurologists. They also
documented the age when they were performed, the
background pattern and presence of seizure activity.
The MRI scans were assessed by an experienced neuro-
radiologist who was blinded to the clinical course and
outcomes. The appearances of the BGT, posterior limb of
the internal capsule, white matter and cortex were recorded
and classified as previously published (12).
The study was approved by the Human Research Ethics
Committee of Stellenbosch University (Ref. No. N10/05/
157).
Statistical analysis
GraphPad software (GraphPad Software Incorporated, La
Jolla, CA, USA) was used for statistical analysis. Fisher’s
exact two-tailed test was used to compare categorical data
and the t-test was used to compare means of continuous
2 ©2016 Foundation Acta Pædiatrica. Published by John Wiley & Sons Ltd
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data. The Bonferroni method was used to correct for
multiple comparisons. StatPlus was used to test for the
normality of continuous variables.
RESULTS
Data were available on 99 of the 100 treated infants and the
main demographic and perinatal data are shown in Table 1.
Neonatal clinical course
Using the Thompson score, encephalopathy was classified
as mild in 32% of infants, moderate in 45% and severe in
23%. There were three infants who were not classified due
to missing data. Table 2 shows the main clinical course and
complications.
Of the 48% infants with abnormal coagulation, 14% were
treated with vitamin K and fresh frozen plasma, although
none had severe bleeding.
Most infants (91%) received some sedative or anti-
convulsant medication: 45% received just phenobarbitone
and the remainder received phenobarbitone plus one or two
other anti-convulsants – midazolam and lignocaine infu-
sions – for refractory seizures.
The majority of infants received total parenteral nutrition
during cooling and commenced enteral feeding after this.
The average time taken to full enteral feeds was 7.5 (3.5)
days, with 65% of the infants receiving cup feeds – the
routine method for feeding infants who are not breastfeed-
ing but have a safe swallowing mechanism in this institution
– 26% receiving breastfeeding and 9% receiving tube
feeding.
The median age at discharge (66%) or transfer to another
facility (34%) was nine (range 5–46) days. By this time, 88%
of infants were receiving some breastfeeding, 8.7% were on
cup feeding and 3% were receiving tube feeding.
Some infants still had abnormal levels of consciousness
(16%) and tone abnormalities (27%) at discharge or
transfer, including one who was still tube-fed when he died
on day 30.
Monitoring and imaging
Of the 78 aEEG recordings that were available, four were
unsuitable for assessment (Table 3). The median duration of
recordings was 73 hours (range 5–168). Within the first
24 hours, 36 showed infants showed severely abnormal
background patterns and nine showed moderately abnor-
mal background patterns, with 18 recovering within
48 hours of birth but 13 showing no recovery during the
period of recording. Only eight infants had normal sleep–
wake cycling during the time of recording. Some seizure
activity was seen in 72% of recordings and 46% (26/56) of
them had a high seizure burden.
Formal EEGs were performed in 30 infants at a median
age of five days (range 1–12). Severely abnormal back-
ground patterns were seen in 22, with seizure activity in
three. Of these infants, 11 had not had previous aEEG
recordings and eight had displayed similar abnormalities in
earlier aEEGs.
At least one cranial ultrasound was performed in 81
infants (Table 4) and the median age at the first scan was
one day (range 1–5). The predominant findings are
Table 1 Perinatal characteristics
n = 99
Maternal characteristics
Maternal age, median (range), years 23.5 (15–46)
Primiparity, n (%) 58/93 (62.3)
HIV positive, n (%) 19/89 (21.3)
Infant characteristics
Male, n (%) 59 (59)
Inborn, n (%) 33 (33)
Gestational age, median (range) weeks 39 (35–43)
Birthweight, median (range) grams 3060 (1960–5190)
Emergency Caesarean section, n (%) 21/98 (21.4)
Sentinel event*, n (%) 8/98 (8.1)
Shoulder dystocia, n (%) 5/98 (5.1)
Apgar at one minute, median (range) 2 (0–6)
Apgar at five minutes, median (range) 4.5 (0–8)
Apgar at 10 minutes, median (range) 6 (1–10)
Apgar at five minutes <5, n (%) 47/97 (48.5)
pH within the first hour, mean  SD 7.03  0.15
pH within the first hour, median (range) 7.02 (6.61–7.4)
pH within the first hour <7.00, n (%) 35/81 (43)
*Sentinel event = uterine rupture, abruptio placentae, cord prolapse, acute
exsanguination.







Duration, days and mean (SD) 1.2 (1.9)
MAS/PPHN 7 (7)
Surfactant lavage 3 (3)
Abnormal coagulation 37/77 (48.1)
Thrombocytopaenia 26/77 (33.8)
Inotropic support 13/77 (16.9)
Infection (suspected and confirmed) 45 (45)
Culture-positive (blood or CSF) 8 (8)
NEC 1 (1)
Renal dysfunction 11/77 (14)




Strong suck at discharge 49/66 (74.2)
Encephalopathic at discharge 11/68 (16.2)
Abnormal tone at discharge 17/62 (27.4)
Neonatal deaths 14 (14%)
*HIE 1: ≤10, HIE 2: 11–14, HIE 3: ≥15 [Thompson et al. (10)].
MAS = Meconium aspiration syndrome; NEC = Necrotising enterocolitis;
PPHN = Persistent pulmonary hypertension of the newborn.
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described in Table 4. The range of BGT abnormalities
included hypodense caudate nucleus, mixed echogenicity
in the BGT, increased echogenicity in the thalamus and
some striatal vasculopathy. There were 91 Doppler studies
carried out at a median age of one day (range 1–5) and eight
had a significantly abnormal resistance index of <0.55.
Brain MRI was performed on 35 infants born during the
routine referral period until April 2011, at a median age of
115 days (range 4–150) and seven infants were scanned
within six weeks of age. As shown in Table 4, findings
associated with a good outcome were documented in 29
infants and those associated with a poor outcome in six.
One infant with mild ventricular dilatation at five months
died at 15 months after surgery for aqueduct stenosis. There
were no other congenital anomalies or other disorders
diagnosed using MRI scans.
Outcomes
Outcome information was available on 67 infants and 33
infants were lost to follow-up. There were no significant
differences in perinatal characteristics, early clinical condi-
tions and neurological status at discharge between the
infants with known and unknown outcomes, except for a
significantly increased number of infants exposed to the
human immunodeficiency virus (HIV) who did not attend
the follow-up. One of these infants was infected and was on
antiretroviral treatment at three months. There was also no
significant difference in MRI findings between infants with
known or unknown outcomes (p = 1.000). There was no
outcome information on 10 (28.6%) of the 35 infants who
had undergone MRI scans. Findings associated with a good
outcome were recorded in eight of the 10 infants and with a
poor outcome in two.
Of the 17 infant deaths, 14 occurred in the neonatal
period and 13 of these followed the withdrawal of intensive
care because of the severity of their illness, based on a
combination of clinical, aEEG and cranial ultrasound
findings. The fourteenth infant with moderate HIE died
from gram-negative septicaemia. Of the three who died
later, one died from acquired immune deficiency syndrome,
another from gastroenteritis and the cause of death of the
third infant was uncertain.
Of the 50 infants assessed at a median age of 12 months
(range 5–12), 41 (82%) had normal neurodevelopment or
had minor abnormalities, such as speech or hearing
impairment, and nine (18%) had severe neurodevelopmen-
tal impairment. Further assessments were planned on 10
infants with minor abnormalities at one year and three had
normal results at the age of three, three had minor speech
delays at 24–35 months, one had autistic features at
18 months and three did not attend further follow ups.
An infant that had normal results at 12 months had
autistic spectrum disorder at a further follow-up and
another with aqueduct stenosis died after surgery at
15 months. HIV exposure was documented in two infants
who were later followed up. One initially had a negative
HIV result, as measured by polymerase chain reaction, and
walked late at 18 months. The other had mild speech delay,
Table 3 Neurophysiological monitoring
aEEG n = 74









High seizure burden 26





EEG n = 30




Generalised low voltage (2 with occasional bursts) 20
Burst suppression 2
Seizures 3
*11 infants not monitored full 72 hours, recovery could not be assessed.
CNV = Continuous normal voltage, DLV = Discontinuous low voltage;
DNV = Discontinuous normal voltage.
Table 4 Imaging
Cranial ultrasounds – number, day imaged and abnormalities
1 scan – median day 1 (1–5) 81
2 scans – median day 4 (2–11) 29
3 scans – median day 4 (3–4) 5







Doppler, total n (1st, 2nd, 3rd) 91 (67, 22, 2)
RI < 0.55, total n (1st, 2nd, 3rd) 8 (5, 3, 0)
MRI brain – abnormalities n = 35
Age at scan in days, median (range) 115 (4–150)
BGT + PLIC 6
Thalamus only 1
White matter 7
Severe with overt infarction 4
Mild-moderate 3
Reduced WM volume 4
WM + PLIC and/or BGT 5
WM + cortex 4
Haemorrhage or thrombosis 2
Cerebellum 2
BGT = Basal ganglia thalami; IVH = Intraventricular haemorrhage;
PLIC = Posterior limb of internal capsule; RI = Resistance index;
WM = White matter.
4 ©2016 Foundation Acta Pædiatrica. Published by John Wiley & Sons Ltd
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which was normal at three years, and was later confirmed to
be negative for HIV.
Predictors of outcomes
At discharge at a median age of nine days (range 5–46), 49
infants had a strong coordinated suck that was sufficient to
feed adequately. Outcomes were available in 33 of them and
29 (87.9%) had a good outcome. Of the four (12.1%) infants
with a good suck but a poor outcome, two had MRI
abnormalities – BGT, posterior limb of internal capsule,
white matter, cortex, pons and sinus thrombosis – and one
had aEEG findings associated with a poor outcome.
Cerebral palsy was diagnosed in three survivors. The fourth
infant did not have any early poor prognostic indicators and
the cause of death was unclear.
The outcome was known in 10 of the 19 infants with a
poor or absent suck at discharge at a median age of 12 days
(range 5–46). The outcome was poor in four (40%) and
good in six (60%). The MRI results, carried out between
seven and 145 days, were normal in three infants with a
poor suck but good outcome and three had no MRIs but
had abnormal aEEG/EEGs at two to six days.
Factors that were significantly associated with poor
outcome were HIE grade three (p = 0.0001), severe aEEG
Table 5 Comparison of outcomes
Poor outcome (n = 26) Favourable outcome (n = 41)
p
(Died/severe neurodevelopmental abnormality) (Normal/mild abnormality)
n (%) n (%)
Maternal data
Age
Mean (SD) 26.95 (7.91) 24.95 (7.31) 0.333
Median (range) 27 (17–43) 22 (17–46)
Primigravida – n (%) 9 (25) 30 (73.2) 0.003
HIV-infected – n (%) 5 (19.2) 5 (12.2) 0.493
Delivery at TBH – n (%) 10 (38.5) 10 (24.4) 0.277
EMCS 6 (23.1) 6 (14.6) 0.515
Infant data
Birth weight (g)
Mean (SD) 3093 (546) 3174 (678) 0.670
Median (range) 3045 (2100–4657) 3070 (1960–5190)
Female 15 (57.7) 12 (29.3) 0.025
Gestation* – n (%)
Pre-term 4 (15.4) 6 (14.6) 1.000
Term 18 (69.2) 26 (63.4) 0.793
Post-term 4 (15.4) 8 (19.5) 0.753
10 minute Apgar <7 – n (%) 13 (50) 15 (36.6) 0.317
ph† <7 – n (%) 13 (50) 11 (26.8) 0.070
HIE‡
Grade 1 4 (15.4) 21 (51.2) 0.004
Grade 2 8 (30.8) 16 (39.0) 0.604
Grade 3 14 (53.8) 4 (9.8) 0.0001
Abnormal Doppler on CrUS (RI < 0.55) 2/19 (10.5) 3/46 (6.5) 0.625
aEEG Severe abnormality 17 (65.4) 6 (14.6) 0.0001
Recovery <48 hours (from severe background) 3/17 (17.6) 4/6 (66.7) 0.045
High seizure burden§ 11 (42.3) 8 (19.5) 0.055
Abnormal MRI 4/5 (80) 1/20 (5) 0.002
Abnormal coagulation 9 (34.6) 12 (29.3) 0.788
Thrombocytopaenia 9 (34.6) 6 (14.6) 0.074
Inotropic support 8 (30.8) 2 (4.9) 0.010
Suspected and confirmed infection 15 (57.7) 14 (34.1) 0.078
Good suck 4 (15.4) 29 (70.7) 0.0001
Encephalopathic at discharge/transfer 5 (19.2) 0 (0) 0.007
Abnormal tone at discharge/transfer 8 (30.8) 2 (4.9) 0.010
*Pre-term: <37 weeks, term: 37–40 weeks, post-term >40 weeks.
†pH within one hour of birth.
‡HIE 1: ≤10, HIE 2: 11–14, HIE 3: ≥15 [Thompson et al. (10)].
§Electrical seizures on aEEG.
Denominators = total assessed.
p-values of variables where there was a significant difference in outcomes in bold.
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background pattern (p = 0.0001), abnormal MRI findings
(p = 0.002), being encephalopathic at discharge (0.007).
Other factors that were associated with poor outcome to a
lesser degree were requiring inotropic support (p = 0.010),
abnormal tone at discharge (p = 0.010), being female
(p = 0.025) and no recovery from severe aEEG within
48 hours (p = 0.045). Having a good suck at discharge
(p = 0.0001), primiparity (p = 0.003) and mild HIE
(p = 0.004) were associated with a favourable outcome
(Table 5). After correcting for multiple comparisons, only
HIE grade three, severe aEEG background and an abnor-
mal MRI were significantly associated with poor outcome.
A normal MRI had a positive predictive value (PPV) of
95%, with a 95% confidence interval (CI) of 76.18–99.88 for
good outcome. Severe aEEG and poor suck at discharge, at
a median age of nine days, had a PPV of 75% (95% CI
20.34–95.88) for poor outcome.
DISCUSSION
We have described a cohort of HIE neonates cooled as part
of their standard clinical care in a middle-income setting in
South Africa. We have previously shown that cooling is
feasible and safe in such a setting (8). The perinatal details
of our cohort were similar to published cohorts (13,14) with
respect to gestational age, birth weight, proportions of male
infants and out-born infants. The differences were the
younger mothers (23 vs 30 years) and a lower Caesarean
section rate in this cohort (21% vs 56.5–69%) (4,14). The
Caesarean section rate in HIE infants was similar to the
general rate of 22.6% at this hospital. There was no
increased incidence of complications associated with either
cooling or HIE (15) when compared to published data
(Table 6).
Of the whole cohort, 17% infants died, 41% showed
normal development or had mild abnormalities and 9% had
severe impairment at one year of age. Of the 10 infants
whose development was not entirely normal at one year of
age, three showed normal development, three had minor
speech abnormalities, one was severely abnormal on the
autistic spectrum and three did not attend further follow up.
Another infant that showed normal development at
12 months was later diagnosed as autistic.
The severity of encephalopathy was assessed using the
peak and duration of the abnormal Thompson HIE score
(10), which is routinely used in this institution. Thompson
reported a PPV of 92% and negative predictive value (NPV)
of 82% for poor outcome at one year, with a peak HIE score
of 15, indicating severe HIE, in the pre-cooling period.
Using the same classification for severity, we also found a
correlation between severe HIE and poor outcome, namely
death or severe neurodevelopmental abnormality at one
year, although with lower predictive values – 73.3% for PPV
and 81.3% for NPV – which might be accounted for by the
incomplete outcome data and the previously described
effect of TH on clinical evaluation (16).
Severe aEEG background activity and no recovery by
48 hours were associated with poor outcome. Artefacts
were found in one-third of the available recordings, making
interpretation difficult. This is higher than the 12%
Table 6 Comparison to TOBY study cooled infants*
TCH (N = 65)† TOBY (N = 163) p
Gestational age, weeks 39 40.3
Median (range) (35–42) (39.1–41.3)
Birthweight, grams 3070 3450
Median (range) (2300–5040) (2957–3853)
Male, n (%) 36 (55.4) 101 (62) 0.373
Apgar at 10 minute, median (range) 6 (1–10) 4 (2–5)
Clinical course and complications, n (%)
Meconium aspiration/PPHN 6 (9.2) 16/163 (10) 1.000
Hypotension 13/51 (25.5) 126/163 (77) 0.0001
Abnormal coagulation 24/51 (47.1) 67/163 (41) 0.517
Thrombocytopaenia 19/51 (37.3) 94/163 (58) 0.016
Culture-positive sepsis 5 (7.7) 20/163 (12) 0.360
Necrotising enterocolitis 1 (1.5) 1/163 (<1) 0.490
Age at discharge, days and median (range) 11 (5–46) 12 (8–18)
Outcomes, n (%)
Normal/mild abnormality 20/28 (71.4) 71/163 (44) 0.008
Severe motor/developmental abnormality 8/28 (28.6) 32/120 (27) 0.817
Died 15/43 (34.9) 42/163 (26) 0.253
Combined death and severe neurodevelopmental abnormality 23/43 (58.1) 74/163 (45) 0.392
*TCH infants assessed at 12 months with Bayley 111 screen.
†Only mod-severe HIE.
Denominators = numbers assessed.
PPHN = Persistent pulmonary hypertension of the newborn.
p-values of variables that were significantly different between the studies in bold.
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previously reported (17). Some were avoidable and high-
lighted a need for on-going training in the correct applica-
tion of aEEG and the need to review recordings in real-time
to check for quality.
It has been shown that early inability to feed orally
following HIE is associated with poor outcome (18). In this
cohort, 88% of those who had established adequate feeding
by discharge had a good outcome, but 60% of infants with
poor suck at discharge had good outcomes at one year. This
might be explained by the overall early discharge dates and
assessment at 14 days, which was only available in three
infants, may be more appropriate.
In total, 111 abnormal findings consistent with previously
described findings in term infants following perinatal
asphyxia (19) were noted on cranial ultrasound (Table 4).
None had signs that suggested congenital malformations or
infection. There was no association with any specific cranial
ultrasound findings and outcomes. Several factors may
account for this. Most infants only had one scan, the
majority on day one, and in general these were only
performed using just the anterior fontanelle window. It
has been shown that the usefulness of ultrasound in
predicting outcome can be optimised by using newer
machines with better image resolution, using additional
Figure 1 Early and late imaging of same infant.
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acoustic windows, improving the skills of operators and
scanning serially in first two weeks (19,20). In one study,
ultrasound had similar predictive values to MRI scans
carried out in close temporal proximity and reliably
predicted significant motor outcomes in HIE (21). How-
ever, performing serial cranial ultrasound as a matter of
routine is unlikely to be feasible in this setting. It is possible
that the findings that were inconsistent with the MRI scans
and later outcomes were transient abnormalities that would
have resolved if subsequent cranial ultrasound scans had
been performed. This suggests that it might be more
worthwhile to delay the scans to later in the first week.
Only severe cranial ultrasound abnormalities have been
shown to predict outcome (Fig. 1).
In this cohort, MRI was not performed at a consistent
time after birth, but it was found to have a good predictive
value. Both cranial ultrasound and MRI scans were
performed in 25 infants and there was no good correlation
between the two imaging modalities. The frequently large
time interval between techniques may account for this
(20). Cerebral palsy was diagnosed in two-thirds of infants
with abnormal features shown on MRI scans at 3.0–
4.5 months (Figs 1 and 2), together with the outcome
information that was available. This study confirmed that
MRI was a good surrogate marker for later outcome.
Although it is not universally accessible in low-resource
settings, it could be used as a surrogate marker to assess
interventions in a setting such as our hospital. To limit
demand on limited scanning time, it may be valuable to
target those infants with abnormal neurological exams at
discharge for further imaging with cranial ultrasound and,
or, MRI scans.
The maternal HIV infection rate was similar to that in the
local population during the study period (22) and it is not
clear what impact HIV exposure had on later outcome.
There were more HIV-exposed infants in the group that
were lost to follow-up. However, HIV exposure did not
appear to influence outcome in those infants where
outcome data were available. Information about the moth-
ers’ treatment was not documented.
When we compared the information available on infants
with moderate to severe HIE to the TOBY study, our
cohort had more infants with no abnormalities or minor
abnormalities at follow-up (Table 6) and did not have
more complications. These comparisons need to be inter-
preted in light of the fact that a large proportion of our
cohort (33%) had no follow-up data and the strict aEEG
entry criteria and clinical assessment used in the TOBY
trial. Our study infants were also assessed earlier, at the age
of 12 months, using Bayley-III screening rather than the
full Bayley scales.
Similar numbers with necrotising enterocolitis (NEC)
(1%) and meconium aspiration syndrome/persistent pul-
monary hypertension of the newborn (7%) were found as in
a UK cooling registry (15). The low number with NEC is
significant in this population with 21% HIV exposure, as
there has been a reported association between maternal
HIV infection and increased risk of NEC (23). There were
two infants who were exposed to HIV, but were not
infected, who had persisting abnormalities after one year.
This highlights an interesting confounding factor for future
studies, as there is some evidence that HIV exposure may
cause subtle neurodevelopmental impairments in less
developed countries (24).
This study had several limitations. Because of its
retrospective nature, some demographic, maternal and
neonatal data, such as HIV stage of disease and treatment
and feeding ability in the late neonatal period, were not
available for analysis. Cranial ultrasounds were not
sequentially performed and details about the timing and
evolution of findings were not systematically recorded.
Limited access to MRI scans resulted in a wide range of
imaging times and inadequate staff training on aEEG
meant that 30% of recordings could not be interpreted.
The follow-up rate was suboptimal and this restricted the
analysis between prognostic factors and outcome. Differ-
ent strategies to improve this will be attempted in the
future, including tracking through attendance at other
clinics and accessing the Home Affairs Department deaths
registry.
MRI at 4.5 months: T1 weighted imaging in the axial plane 
showing  bilateral abnormal increased signal intensity in the 
lentiform nuclei. (long arrow) There is additional bilateral 
increased signal in the thalami (short arrow) and reduced 
signal from myelin within the internal capsule (arrowhead).
Outcome: Spastic quadriplegia, epilepsy at 1 year.
Figure 2 MRI at 4.5 months. MRI = Magnetic resonance imaging.
8 ©2016 Foundation Acta Pædiatrica. Published by John Wiley & Sons Ltd
Therapeutic hypothermia in a middle-income country Kali et al.
75
Stellenbosch University https://scholar.sun.ac.za
A strength of our study was that it is one of the larger
studies of TH in this setting and it showed that if TH was
applied within a strict protocol, as recommended by
international regulatory organisations (25), it can be safe,
even in less well-resourced settings. Other studies in similar
settings have used different cooling methods, had small
numbers and may not have always had access to adequate
monitoring facilities (6,7). No other studies including MRI
and follow-up data have been published to date in such a
setting.
Some factors associated with outcome, such as severity of
encephalopathy and aEEG abnormalities, were similar to
those found in one of the large cooling trials (26). Future
studies should aim to use the previously described tools,
such as a threshold Thompson HIE score of 16 (27) to
select suitable infants and predictors of outcome, such as
aEEG at 48 hours and MRI scans (28,29), to assess further
interventions in combination with cooling.
CONCLUSION
We have shown that the majority of cooled survivors in our
setting did not develop major impairments. Continual
training on cooling criteria and the use of cranial ultra-
sound and aEEG is required. MRI is a good predictor of
neurodevelopmental outcome and could be used as a
surrogate biomarker in new prospective studies. However,
a more feasible strategy in these settings might be to select
infants with abnormal neurological function at discharge
for further imaging with cranial ultrasound or MRI, to
identify those who are likely to develop neurodevelopmen-
tal impairment.
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Therapeutic hypothermia (TH)  improves outcomes in infants with hypoxic ischaemic 
encephalopathy (HIE) and is now standard of care in many settings. However, the 
beneficial effects are limited. One previous study, the neo.nEURO.network Trial in 
which all the infants received morphine co-treatment, showed a greater effect of TH 
compared to other studies. 
Objectives  
We aimed to determine whether combining TH with morphine would improve intact 
survival at 18 months in infants with HIE compared to TH  alone. 
Methods 
We prospectively randomized 48 infants admitted to Tygerberg Hospital for cooling 
between 2012 and 2016 to receive TH-only (TH) or TH-plus-morphine (TH+M). 
Cooling was administered for 72 hours according to the local protocol. The morphine 
group additionally received the drug at 25µg/kg/hr during TH . Serial morphine 
concentrations were measured in the serum and cerebrospinal fluid. 
Neurodevelopmental assessments were performed until 18 months. 
Results 
45 infants were included. Median maternal age was 23 (17-42) years, gestational age 
38 (36-42) weeks, birthweight 3140 (2150-4745) g.  8.9% infants were HIV exposed; 
46.7% were inborn. Median time to initiation of TH  was 4.3 hours. There were no 
differences in the baseline characteristics between the groups. Group TH had a higher 
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seizure burden, 13[59.1%] vs 3[13%] (p=0.002) and liver dysfunction, 8[36.4%]  vs 
2[8.7%] (p=0.035) compared to TH+M. No differences were noted in ventilatory or 
inotropic support, length of admission, neurological condition at discharge nor severe 
MRI abnormalities.  
There was an absolute risk reduction of 28% in the composite outcome of death or 
neurodevelopmental impairment in the therapeutic hypothermia-plus-morphine group 
which was not significant (p=0.087). The other measured outcomes also showed no 
significant differences: normal outcome at 18 months (17[89.5%] TH+M vs 9[72%] TH, 
p=0.286); number of deaths (5[22.7%] TH vs 2[8.7%] TH+M, p=0.243) and abnormal 
neurodevelopment (3[25%] TH vs 2[10.5%] TH+M, p=0.350).  
Conclusion 
In this cohort, therapeutic hypothermia-plus-morphine was associated with some 
improved early clinical markers (seizure burden and liver dysfunction), without 
increased complications or duration of hospital stay. While there were differences in 
later outcome, these were not statistically significant. 
Trial registration - www.pactr.org; Identifier: PACTR202006515915908 
Introduction  
Worldwide, intrapartum complications resulting in hypoxic ischaemic encephalopathy 
(HIE) remain a leading cause of neonatal deaths (1). The only treatment that has been 
shown to improve outcomes in infants with HIE (2), and that is now standard of care 
in many settings, is therapeutic hypothermia (cooling). We have previously shown that 
cooling in our setting is safe and the majority of survivors were normal or had minimal 
impairments at 1 year of age (3,4). However, the beneficial effects of cooling compared 
80
Stellenbosch University https://scholar.sun.ac.za
to normothermia are limited, with many infants worldwide still having poor long-term 
outcomes. There is consequently a need to test combination therapies that may 
complement the effects of cooling. One previous study, the neo.nEURO.network Trial, 
showed a greater treatment effect of cooling compared to some of the other large 
studies. A possible explanation was that all the infants in this study received morphine 
sedation at a relatively high dose as part of their treatment. There is some evidence 
that morphine may have immune-modulatory functions which we postulate may 
influence some of the inflammatory pathways that are involved in the injury process 
following a hypoxic ischaemic insult, and thus limit damage (5,6). It may also be related 
to a reduced stress response to hypothermia as it has been shown in animal studies 
that the beneficial effect of cooling is negated in the absence of sedation(7).  
We therefore sought to explore whether morphine conferred additional 
neuroprotective properties to cooling alone in neonates with HIE. 
Objectives 
• To describe and compare the clinical course of infants treated with therapeutic 
hypothermia plus morphine (TH+M) and with therapeutic hypothermia alone 
(TH). 
• To determine whether infants treated with TH+M had better short-term and 
long-term outcomes when compared to TH alone.  
Ethical approval 
Ethical approval to conduct the study was obtained from the Human Research Ethics 
Committee of Stellenbosch University (N10/05/157), and also from the management 
of Tygerberg Hospital (TBH). 
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Written informed consent was obtained from the parents of all the included infants. 
Methods 
Setting 
The study was conducted from March 2012 to June 2016 in the neonatal intensive 
care unit (NICU) of Tygerberg Hospital. This is a tertiary hospital with a total 124 
neonatal beds (8 intensive care, 4 high care), which also admits referrals from a large 
rural Western Cape drainage area. Total annual deliveries at the hospital ranged from 
7855-8008 during the study period. The NICU admits approximately 500 infants/year 
and has offered a cooling service for neonates presenting with HIE as standard care 
since 2008.  The service cools up to 100 neonates annually. 46% (45/97) of cooled 
infants in 2016 were inborn.  
Infants with gestational age ≥36 weeks and birth weight ≥1.8kg were selected for TH 
according to criteria based on the TOBY study as previously described (4,8), including 
an initial Thompson HIE score of at least 7 (9). 
Patient selection and management 
This was a non-blinded randomised controlled trial. All infants referred to the NICU for 
therapeutic hypothermia (TH) with a suspected diagnosis of HIE who were >1.8kg and 
had a getstaional age >36 weeks were eligible for the study. They were recruited and 
allocated to a treatment arm according to random computer generated numbers, to 
receive either TH alone or TH+M at a dose of 25µg/kg/hr for the duration of the cooling 
period (72 hours). Infants not in the morphine group were sedated with 
phenobarbitone, benzodiazepines or clonidine when needed.  
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We excluded infants with these criteria: presence of congenital abnormalities or 
abnormalities requiring surgery within the first three days, admission outside of 6 hours 
of birth, intensive care not offered because of severity of encephalopathy. 
Infants were managed according to the standard TBH cooling guidelines (based on 
TOBY protocol) for 72 hours, and re-warmed at a rate of not greater than 0.5°C/hr. 
Cooling systems used were Tecotherm TSmed 200 N or the Blanketrol III.  
Serial samples  were collected for measuring morphine concentrations in serum and 
cerebrospinal fluid as well as inflammatory cytokines and chemokines, at pre-specified 
time points. Analysis of this data is the subject of another paper.  
All the infants had at least one ultrasound scan of the brain performed during the 
admission. 
MR imaging was acquired where possible. This was done under general anaesthesia 
(routine at this hospital) using a Siemens Magneton Symphony 1.5 Tesla magnet 
(Siemens Healthcare, Erlangen, Germany) with T1, T2 and diffusion weighted 
sequences. 
After discharge, infants were followed up in a high risk clinic by a single experienced 
neurodevelopmental specialist from 3 months up to 18 months of age, who was blind 
to treatment arm. The examinations included a basic neurological examination with 
test positions and angles as described by Amiel-Tison (10), and assessment using the 
Bayley Scales of Infant and Toddler Development-Third Edition (BSID-III). Hearing 
was also assessed using otoacoustic emissions and automated auditory brainstem 
responses in the first three months, and visual reinforcement audiometry at one year. 
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General movements at 12-15 weeks were recorded (11,12), and analsysis of this data 
is still ongoing. 
Study measurements and procedures 
Clinical information was collated from routinely used cooling data collection forms and 
the electronic record of medical notes, and transcribed into a secure electronic 
database. 
Severity of initial encephalopathy was assessed based on Thompson score: moderate 
7-14, severe ≥15 (9).  
Cranial ultrasound scans were assessed by a single reviewer and the following 
findings were recorded: day imaged; evidence of cysts within ventricles (sub-
ependymal, choroid plexus); cerebral oedema; abnormalities in basal ganglia and 
thalami (BGT), white matter, cortex; intra-ventricular haemorrhage; infarction and 
other abnormalities. The results of Doppler studies, and day acquired,  indicating the 
value of the resistance index were documented.  
MRI images were assessed by an experienced neuro-radiologist who was blinded to 
the early clinical course and later outcomes. The appearances of the BGT, posterior 
limb of the internal capsule, white matter and cortex were recorded and classified as 
previously published (13).  
 At follow up assessments, infants were considered severely impaired if they had 
cerebral palsy, were deaf or blind, or had significant developmental delay as defined 
by a composite score of <70 (<2SD below mean) in any of the BSID-III domains 




GraphPad software (GraphPad Software Incorporated, La Jolla, CA, USA) and 
Stata  15 (College Station, Texas USA.) were used for statistical analysis. We 
summarized continuous variables using mean (standard deviation) or median (range) 
depending on the distribution, and categorical variables using count (percent).  We 
used Chi-squared test or Fisher’s exact test to test associations between categorical 
variables and the t test or Wilcoxon rank-sum test to compare continuous variables 
between groups. We performed a logistic regression to determine the odds of a normal 
outcome following TH+M treatment. We set statistical significance at p< 0.05. 
Results 
Clinical course 
Forty-eight infants were recruited to the study. Three were subsequently excluded; 1 
had trigonocephaly and dysmorphic features and 2 only commenced cooling after 7 
hours of age (Figure 6.1).  
Of the remaining 45 infants, 22 received TH alone and 23 received  TH+M. 
Baseline characteristics and clinical condition of all study infants are depicted in Table 
6.1. 
Median maternal age was 23 (range 17-42) years. Twenty eight (62%) of them were 
primiparous, and 4 (8.9%) were HIV positive. 
Sixty four percent (29) of the infants were male; 46.7% (21) were inborn.    
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There were no significant differences in the baseline characteristics of the two groups 
of infants (see Table 6.1). Time to admission for cooling and to target temperature 
were  similar between the groups. 
Thirty eight (84%) of the infants had moderate and seven (16%) severe HIE. 
The clinical course of all study infants is depicted in Table 6.2. 
Twenty seven infants required ventilation for a mean duration of 5.5(±2.7) days. The 
TH+M group had no significantly increased duration of ventilation (p=0.206). 
Of the 24(53%) infants with coagulation abnormality and 19(42%) with 
thrombocytopaenia, three had clinical bleeding requiring treatment (one in TH+M 
group and two in TH group, p=0.608).  
Within the two groups similar proportions of infants (3/23[13%] TH+M vs 2/22[9.1%] 
TH; p=1.000) required more than one inotrope. 
The TH+M group had significantly less infants with liver dysfunction (ALT>100 IU/L)  
and with a high seizure burden (defined by the number of anti-seizure medications 
used). 
There were no significant differences in time taken to establish feeding or duration of 
admission between the groups; nor in neurological condition at time of discharge as 
evidenced by level of consciousness (p=0.746) or tone abnormalities (p=1.000). 
Imaging  
80 cranial ultrasound scans were performed on the infants, and all infants had a 
minimum of 1 scan (Table 6.3). Up to 3 scans on each infant were performed at median 
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ages of 2 (1-8), 5 (2-12) and 8 (7-27) days for the first, second and third scans 
respectively. 
71 doppler studies were performed and significantly abnormal flow velocities (RI≤0.55) 
were found in 16 studies on 14 infants, the majority (12/16) of them on days 2-3. 
25/45 (55.6%) infants (24 survivors) had MRI imaging, at a median age of 15 (range 
7-256) days (Table 6.3). Of these infants, 20 (80%) had findings associated with a 
normal outcome or minor abnormalities, and 5 (20%) had findings associated with 
abnormal outcome.  
Imaging findings did not differ between treatment groups. 
There was, however, a difference in imaging findings when classified according to 
outcome at 18 months (see Table 6.4). All 3 infants who had severe BGT abnormalities 
on US, and 2/3 of those with severe WM abnormalities had poor outcome. These 
severe changes appeared on later imaging between days 6-27, with severe BGT 
abnormalities being most significant. 
On MRI, the 2 infants who had severely abnormal findings and normal outcome had 
abnormalities in white matter and cortex only. One of them had a relatively small focal 
right-sided infarct both on ultrasound at 7 days and MRI at 3 months of age, not 
involving the corticospinal tracts  (Figure 6.1). The other infant with severe findings 
was still normal at 3 years of age. The remaining 3 infants with severely abnormal 
findings had abnormal outcome in keeping with the MRI findings (Figures 6.2 & 6.3). 
Of the 20 infants with normal  MRI imaging or minor abnormalities, 17 (85%) had 
normal outcome at 18 months; one infant had a sudden deterioration around 1 year of 
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age due to acute hydrocephalus and had an abnormal outcome most likely secondary 
to this; the outcome of 2 infants was not known. 
Outcomes  
Primary outcome - 18 months 
Outcome information at 18 months was available for 38 (84.4%) of the 45 infants, 7 
(15.6%) were lost to follow up (Table 6.5). Seven infants had died, one of them after 
the neonatal period. It was possible to perform neurodevelopmental assessments on 
31/38 (81.6%) surviving infants at this time point. Twenty-six (83.9%) had normal 
neurodevelopment or minor abnormalities, and 5 (16.1%) had abnormal 
neurodevelopment. Overall, 12 infants had an adverse outcome (31.6%) at 18 months. 
Of the twenty-six infants who were normal or had minor abnormalities such as residual 
Erb’s palsy or strabismus at 18 months,  17/19 (89.5%) were in the TH+M group and 
9/12 (75%) in the TH group; p=0.286. We found statistically insignificant increased 
odds of normal outcome following  TH+M treatment, OR 3.78 [95% CI, 0.89-16.05; 
p=0.072]. This was unchanged after imputing for missing outcome data (Table 6.5). 
Of the twelve infants that had the composite outcome of death or severe 
neurodevelopmental impairment,  4/21  (19.0%) were in the TH+M group and 8/17 
(47.1%) were in the TH group; p= 0.087.  
Of the five (16.1%) infants who had severely abnormal neurodevelopment, 2/19 
(10.5%) were in the TH+M and 3/12  (25%) were in TH group; p=0.350. One infant in 
the severely abnormal group also developed bilateral sensorineural hearing loss, and 
required hearing aids. 
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Seven (15.6%) infants had died by 18 months, 2/23 (8.7%) in the TH+M group and 
5/22 (22.7%) in the TH group; p=0.243. 6 died during the neonatal period and 1 
thereafter (from a suspected respiratory infection). At a review at 3 months, this infant 
was already very abnormal with developmental delay and spastic quadriplegia. He 
subsequently defaulted further follow up appointments before he died. Of the 6 
neonatal deaths, 1 died within 24 hours from severe encephalopathy, 4 had care 
redirected due to severity of illness and one had methicillin resistant staphylococcus 
aureus (MRSA) septicaemia. 
35 infants had some longer term follow up and were seen at either 12 or 18 months. 
Four were not seen at either of these 2 time points. Of these 4 infants, one was normal 
at 3 months of age; another had tone and reflex abnormalities at 3 months, but was 
thought to be normal at 9 months. 
There were no significant differences between the infants whose outcome was known 
and those with unknown outcome (S1 Table). 
Primary outcome - 12 months 
Six (13.3%) infants had died during the neonatal period, 5 of them from severe HIE 
and one from infection. Thirty-four (87.2%) of the 39 survivors presented at the 12 
month appointment; 5 (12.8%) did not attend follow up appointments. However, 2 of 
the infants that attended could not be assessed: one had developed acute 




Of the 32 infants that were assessed, 27 (84.4%) had normal neurodevelopment or 
minor abnormalities and 5 (15.6%) were categorised as having severely abnormal 
neurodevelopment. 
There were no significant differences in outcome at this time point between the TH 
and TH+M groups. 
Discussion 
In this randomised controlled trial comparing treatment of infants with HIE with TH 
alone and with TH plus Morphine, we found differences in intact survival to 18 months 
of age but these did not reach statistical significance. There was no significant 
difference in the composite outcome of death or severe neurodevelopmental 
impairment. Mortality and severe disability were also not significantly reduced when 
assessed separately. We found improvements in some short-term clinical outcomes 
and did not find increased adverse events in the TH+M treated group. 
During the initial admission the TH+M treated infants had some improved clinical 
markers, with significantly less liver dysfunction and a lower seizure burden. A possible 
explanation might be that there was a lower proportion of infants with severe HIE in 
the TH+M group, but this difference was not statistically different and infants with 
severe HIE constituted a small fraction of the whole cohort (15.6%). 
The adverse events that could be anticipated with such a high dosage of morphine 
that have been described in other papers (14,15) were not observed in this study. 
Unlike in the paper by Liow et al (15), there was no significant increase in hypotension 
requiring inotropic support, requirement and duration of ventilation (see Table 6.2) and 
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no increased length of stay in the morphine group despite a consistently higher dose 
administered for 72 hours. 
Other clinical findings that have been shown to be surrogate indicators of extent of 
brain injury and to predict outcome (16), such as ability to establish feeds and 
neurological condition at time of discharge, were not different between the two groups. 
Our findings that the majority of those infants who had severe BGT and WM 
abnormalities on later US imaging had poor outcomes were similar to what has been 
reported in literature, that the more significant findings associated with poor outcome 
may appear later in the postnatal course or become more prominent with time (17,18). 
Using a score similar to that used by Tann et al in a Ugandan study (19), we found 
that having ≥2 significant US abnormalities had a PPV of 67% and a NPV of 71.4% 
for poor outcome. Using severe BGT abnormalities alone, the PPV was 99.9% and 
NPV 74.3%. 
Abnormal flow velocities with low resistance index (RI) <0.55 on doppler studies were 
found in 55% of infants with poor outcome vs 20% with favourable outcome, p=0.056. 
This is consistent with recent literature which has shown that an abnormally low RI, 
which was previously known to predict poor outcome in the pre-cooling era, may not 
be as predictive during cooling. A few studies reported that a low RI (<0.55 or <0.6) 
predicted poor outcome before or after the cooling period, but not during cooling 
(20,21). In our study, an RI <0.55 during TH had a PPV of 55% and NPV of 78% for 
poor outcome, which was similar to the findings of Elstad et al who reported a PPV of 
60% and a NPV of 78% (22). 
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MRI imaging findings, in keeping with previously published studies (13,16,23), 
correlated well with outcome. 17/19 (89.5%) of infants with a good outcome that were 
imaged had normal studies or minor abnormalities; whereas ¾ (75%) of those with 
poor outcome had significant abnormalities consistent with the outcome on imaging. 
In the one infant who had a poor outcome and minor abnormalities on initial MRI, the 
outcome was thought to be unrelated to HIE and his subsequent MRI imaging was 
severely abnormal. MRI had a sensitivity of 90% and a positive predictive value of 
95% for normal outcome.   
Although the study by Liow did not show any benefit of routine morphine sedation 
during TH, they also did not show any additional brain injury on MRI and MRS. 
There was an important difference between our study and the Liow study (the only 
study we’ve found looking specifically at this question). Although much larger, theirs 
was a secondary analysis of a multicentre study. Morphine sedation was administered 
as part of routine care at individual clinicians’ discretion and for differing unspecified 
indications. Consequently, there was a wide range of dosages and no standard 
duration of administration. In our study the treatment was prospectively and randomly 
allocated, and the dosage and duration of administration was standardised. 
Our data are more consistent with the study by Angeles et al (24), which suggested 
that in infants with neonatal encephalopathy that were subjected to the repeated 
stressful procedures that are frequently performed in NICUs, opiate treatment did not 
cause more morbidity and might even confer some neuroprotection when assessed 
with MR spectroscopy. 
We defined abnormal outcome as cerebral palsy, blindness, deafness or a score of 
<70 (<2SD below mean) on any Bayley III composite score. There are some concerns 
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in the literature that using a cut-off of <70 to define severe neurodevelopmental delay 
might result in underestimating the prevalence of developmental delay. However, a 
recent study done in a similar population showed that using this cut-off was 
appropriate (25). Looking at our data, only 2 infants who were considered normal by 
these criteria would have fallen into the at-risk category (any Bayley III composite 
score <85/<1SD below mean). One infant (in the TH group) had a cognitive score of 
80, but was very uncooperative and there had been only one opportunity to test him. 
The other one (in the TH+M group) had a motor score of 82. He was a later walker, 
which accounted for the low score but he had no upper motor neuron signs or other 
problems.  
It is not clear why there was a trend towards more infants in the TH+M group surviving 
with a normal outcome, which is contrary to what was recently published regarding 
morphine sedation with cooling (15). The fact that there was less liver dysfunction and 
a lower seizure burden in the TH+M group, may be indicative of some immune 
modulating effects related to morphine treatment. These are currently being explored 
by the authors. Another consideration is the fact that seizures are thought to contribute 
to neurological injury in the setting of HIE (26), and evidence from animal studies 
suggesting that anti-seizure medications themselves may cause apoptotic 
neurodegeneration (27). This may have a role in those infants experiencing fewer 
seizures and anti-seizure medication tending to have a more favourable outcome. 
Globally, it appears that it has been accepted that current protocols for TH (duration & 
depth of cooling) are optimal (28). What is required is that units focus on applying TH 
protocols timeously and rigorously, and to test combination therapies that may 
augment the TH effect. While doing this we need to explore mechanisms by which 
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they may act (many overlap), to ensure they are complementary and do not negate 
each other (29). 
In our study, neither of the groups were commenced on cooling within 3-4 hours, which 
has been shown to improve motor outcomes (30). Despite aiming for this window 
period to commence TH, we were constrained by competing needs and the lack of a 
specialised paediatric/neonatal transport team at the time of recruitment. It is 
conceivable that earlier cooling might have shown a better effect of TH+M.  
Limitations  
A major limitation of the study is that we recuited 60% of the number of patients that 
would have been required to be adequately powered. This may have accounted for 
the lack of statistical significance in the outcomes we measured.  
Data on outcome was missing for 16% of patients, who did not attend follow up 
assessments as planned. This is a common problem in our system with very mobile 
communities, and various strategies are attempted in order to maximise follow up 
information such as accessing the national death registry for mortality data and 
monitoring attendance at other clinics.  
This is, however, an improvement on the loss to follow up rate of 33% we previously 
published in this setting (4). It is hoped there can be further improvements in future 
studies, with the progressive introduction of unified systems of patient data 
management in the province. 
Although all the patients had real time aEEG recordings which were used as part of 
their clinical assessment and used in conjunction with the Thompson HIE score to 
grade severity of encephalopathy and diagnose seizures, we have not described the 
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findings in our results due to loss of captured data (becoming corrupted during attempt 
to download) which meant the recordings could not be rigorously classified and 
reported.   
Another possible limitation is that we did not correct for the possible effects of the other 
sedative medications on outcome as it would be difficult to tease out which effects are 
the result of the seizures or of the treatment. However, a majority of infants in both 
groups received some sedation other than morphine, and there was no significant 
difference between the groups (Table 6.2). 
Strengths 
Although the study did not show the desired outcome, it is the only study we have 
found to date looking in a controlled fashion/systematically at the effects on 
neurodevelopmental outcome of combining morphine sedation with TH. The lack of a 
statistically significant positive effect may be due to the relatively small numbers, and 
could still be clinically important. Our findings of a trend towards more survival with 
normal outcome at 18 months are similar to those from the TOBY study (8), which 
despite showing no significant effect on the primary outcome of death or severe 
impairment found increased survival with favourable neurological outcomes following 
TH treatment. Further work is ongoing to assess blood and CSF levels of morphine 
and inflammatory markers, and explore these interactions. 
Conclusion 
In this cohort, cooling-plus-morphine was associated with some improved early clinical 
markers and was not associated with increased complications or prolonged hospital 
stay, but did not significantly reduce mortality or disability at 18 months. 
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High dose morphine can therefore not be recommended for routine use in infants with 
HIE that are being cooled at this stage. Potential benefits need to be confirmed in 
larger adequately powered studies whilst exploring mechanisms of possible additional 
neuroprotection.  
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Table 6.1: Baseline characteristics of participants by study treatment arm 
Characteristics Hypothermia + 
Morphine  




(Group 2)       
N=22  
P-value 
Maternal age, mean (SD), 
years 
26.1 (6.2) 23.3 (6.1) 0.133 
Primiparity, n (%) 13 (57) 15 (68) 0.420 
Inborn, n (%) 11 (48) 10 (46) 0.873 
Gestational age, mean (SD), 
weeks 
38.9 (1.5) 38.3 (1.5) 0.350 
Birthweight, mean  (SD), 
grams 
3263 (646) 3172 (466) 0.592 
Male, n (%) 15 (65) 14 (64) 0.761 
Head circumference, mean 
(SD), cm 
35.1 (1.9) 35.7 (1.9) 0.360 
Sentinel event*, n (%) 7 (30) 6 (27) 0.815 
Apgar at 5 minutes <5, n (%) 7 (30) 8 (36) 0.673 
pH within 1st hour <7, n (%) 11 (48) 12 (55) 0.652 
Time to admission, h 
mean (SD) 
4.4 (1.3) 4 (1.6) 0.362 
Time to target (33.5°C), h 
mean (SD) 
7.1 (2.8) 6.13 (2.3) 0.204 
HIE 2 #, n (%) 21 (91) 17 (77) 0.194 
HIE 3#, n (%)  2 (9) 5 (23) 0.243 
*sentinel event: cord prolapse, abruptio placentae, uterine rupture, eclampsia 
#HIE 2: Thompson score 7-14; HIE 3: Thompson score ≥1 
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Table 6.2: Neonatal course of infants by treatment group 
Clinical course and 
complications 
Hypothermia + 






Ventilated, n (%) 16 (70) 11 (50) 0.231 
Duration of ventilation, 
days 
Mean (SD) 
4.4 (4.0) 2.9 (3.7) 0.206 
MAS/PPHN, n (%) 5 (22) 4 (18) 1.000 
Inotropic support, n (%) 6 (26) 4 (18) 0.722 
Coagulation abnormality, n 
(%) 
11 (48) 13 (59) 0.554 
Thrombocytopaenia, n (%) 11 (48) 8 (36) 0.550 
Culture-positive infection, n 
(%) 
4 (17) 1 (5) 0.346 
NEC, n (%) 1 (4) 1 (5) 1.000 
Renal dysfunction, n (%) * 5 (22) 8 (36) 0.337 
Liver dysfunction, n (%) * 2 (9) 8 (36) 0.035 
ALT, median (range) 28 (11-319) 37 (13-452) 0.119 
Hypoglycaemia, n (%) # 9 (39) 8 (36) 1.000 
Hyperglycaemia, n (%) 4 (17) 7 (32) 0.314 
Any sedatives, n (%) 17 (74) 20 (91) 0.242 
Significant seizure burden, 
n (%) $ 
3 (13) 13 (59) 0.002 
LOS, days - mean (SD) 12.7 (5.9) 11.9 (6.9) 0.699 
MAS=meconium aspiration syndrome. PPHN=persistent pulmonary hypertension of the newborn. NEC=necrotising enterocolitis. 
ALT=alanine transaminase. LOS=length of stay. 
* Early transient 
# Both early transient & requiring treatment (only 1 required treatment, in morphine grp) 











CUS (n) N=40 N=40 
 
• BGT 29 27 0.808 
• White matter/cortex 34 33 1.000 
• Infarct 1 1 1.000 
• Doppler abnormal (RI=/<0.55)  10 6 0.402 
MRI (n) N=15 N=10 
 
• Moderate-severe BGT 1 2  0.544 
• BGT + PLIC 0 2 0.150 
• White matter ± cortex 











• *WM + BGT ± PLIC 1 2 0.544 
• Haemorrhage or thrombosis 9 4 0.428 
• Cerebellum (mild) 3 3 0.653 
• Brainstem 0 2 0.150 
CUS=cranial ultrasound scan. BGT=basal ganglia thalami. IVH=intraventricular haemorrhage. RI=resistance index. 
PLIC=posterior limb of internal capsule. WM=white matter 
*WM + BGT – mild in TH+M group 
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Table 6.4: HIE grade and imaging findings by outcome 
Clinical/radiological feature Favorable 
outcome 






HIE 2 25 (96.2) 6 (50) 0.002 
HIE 3 1 (3.8) 6 (50) 0.002 
CUS abnormalities: 
   
Severe BGT 0 (0) 3 (25) 0.026 
Severe WM-cortex 1 (3.8) 2 (16.7) 0.230 
RI </= 0.55 5/25 (20) 6/11 (54.5) 0.056 
MRI abnormalities: (N=19) (N=4) 
 
Severe WM + cortex 2 (10.5) 3 (75) 0.021 
Severe WM + moderate-severe 
BGT + PLIC 
0 (0) 2 (50) 0.024 
Moderate-severe BGT + severe 
WM + cortex 
0 (0) 3 (75) 0.014 
Brainstem 0 (0) 2 (50) 0.024 
HIE=hypoxic ischaemic encephalopathy. HIE 2=moderate encephalopathy; HIE 3=severe encephalopathy. CUS=cranial 
ultrasound scan. BGT=basal ganglia thalami. WM=white matter. PLIC=posterior limb of internal capsule 
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+ Morphine  






























4/21 (19.0) 8/17 (47.1) 0.087   
Lost to follow up, n 
(%) 
2/21 (9.5) 5/17 (29.4) 0.207   
Abnormal, n (%) 2/19 (10.5) 3/12 (25) 0.350   
Death, n (%) 2/23 (8.7) 5/22 (22.7) 0.243   
OR: odds ratio, imputed for missing data; CI: confidence interval.  
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Figure 6.1: Consort flow diagram of recruited and enrolled infants 
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Figure 6.2: MRI image showing a small focal infarction in the territory of the right 
middle cerebral artery but not involving the corticospinal tracts  
Figure 6.3: MRI image showing injury predominantly in white matter and cortex 
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Abstract 
Background 
Sedation with agents such as morphine is frequently recommended for infants 
undergoing therapeutic hypothermia for hypoxic ischemic encephalopathy, despite 
concerns about the paucity of pharmacokinetic data on morphine and possible toxicity 
in these infants. 
Methods 
We conducted a randomised controlled trial to compare outcomes in 45 infants treated 
with therapeutic hypothermia or therapeutic-hypothermia-plus-morphine (at a dose of 
25µg/kg/h) between 2012-2016. For this nested study, we analysed serial serum (at 
109
Stellenbosch University https://scholar.sun.ac.za
24, 72, and 96 hours) and cerebrospinal fluid (72 hours) concentrations of morphine 
and its metabolites (morphine-3-glucuronide and morphine-6-glucuronide) in the 
patients that were treated with therapeutic-hypothermia-plus-morphine in the first 96 
hours after delivery using LC-MSMS.  
Results 
We did not find toxic concentrations at this constant morphine infusion rate. Serum 
concentrations of morphine and metabolites were below 20 µg/L at all time points. 
Mean CSF morphine, morphine-3-glucuronide and morphine-6-glucuronide 
concentrations at 72 hours were 5.19, 3.68 and 0.61µg/L respectively. There were no 
increased complications such as increased length of stay, need for ventilation or 
inotropic support as found in other studies. 
Conclusion 
We found that morphine infusion at 25µg/kg/h was tolerated well in this cohort.  
Trial registration - www.pactr.org; Identifier: PACTR202006515915908 
Keywords 
morphine, neonates, encephalopathy, hypothermia 
Introduction 
Infants with hypoxic ischemic encephalopathy (HIE) undergoing treatment with 
therapeutic hypothermia  frequently receive sedative agents. This is because a 
majority of protocols for therapeutic hypothermia recommend sedation during therapy, 
based on some animal evidence that the neuroprotective effects of therapeutic 
hypothermia may be diminished or even negated if applied without sedation1. There 
is also evidence that encephalopathic infants admitted to neonatal intensive care unit 
(NICU) are often subjected to multiple traumatic and stressful procedures that may 
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add to brain injury as demonstrated on magnetic resonance imaging (MRI) and MR 
spectroscopy, and this may be ameliorated by sedating them with opioids2. 
Although morphine is a commonly used agent for sedation during therapeutic 
hypothermia, there are a number of concerns with using this drug. One important 
concern is that there is not an abundance of data about its pharmacokinetics during 
therapeutic hypothermia in this vulnerable population particularly in cerebrospinal 
fluid, and that it may accumulate to toxic levels. It is known that drug metabolism is 
altered in these patients, both from altered blood flow to the organs that metabolise 
drugs due to the disease process and from the effects of cooling3,4. Old evidence from 
animal studies indicated significantly increased morphine concentrations in plasma 
and cerebrospinal fluid, and resultant side effects during hypothermia5. It has thus 
been suggested that ongoing cooling studies should include drug monitoring 6. 
A published study that analysed morphine concentrations in one site of one of the 
major therapeutic hypothermia trials, showed higher cumulative concentrations in the 
therapeutic hypothermia group, and increasing concentrations as the treatment 
continued. They also showed more frequent instances of toxic concentrations 
(>300ng/mL or µg/L) in the therapeutic hypothermia group and when infusion rates  
exceeded 10µg/kg/h7.   
Morphine exerts its analgesic and sedative effects by activating µ and κ opioid 
receptors. Its major metabolic pathway is via glucuronidation in the liver by the 
UGT2B7 enzyme to morphine-3-glucuronide (M-3-G) and morphine-6-glucuronide (M-
6-G). The metabolites are then cleared by the kidneys. M-6-G has been shown to be 
a strong µ-receptor agonist with an even higher affinity than morphine, and is 
responsible for a substantial part of the analgesic effect after morphine 
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administration8,9. Any impairment in liver or renal function may therefore result in 
accumulation of morphine and/or its metabolites and exaggerated effects. 
A more recent study of morphine pharmacokinetics (PKs) in cooled infants showed 
that morphine clearance was affected by both therapeutic hypothermia (reduced) and 
postnatal age, increasing significantly after re-warming resulting in steady state never 
being reached in the first 5 days. Morphine metabolites, on the other hand, 
accumulated  during the therapeutic hypothermia period but were not as affected by 
postnatal age and so did reach steady state once normothermia was established and 
clearance increased10.  
Pacifici conducted a review of morphine PKs in neonates not undergoing therapeutic 
hypothermia and found that clearance varied with gestational age and birthweight, with 
wide variations particularly in the first few days – a likely reflection of changes in 
hepatic blood flow and immaturity of conjugating systems9. 
Objectives 
In infants with HIE treated with therapeutic hypothermia (TH) alone and with 
therapeutic-hypothermia-plus-morphine (TH+M) we aimed to document serum and 
cerebrospinal fluid morphine concentrations in the first 96 hours after birth, and to 
document serum and cerebrospinal fluid concentrations of morphine metabolites 
(morphine-3-glucuronide and morphine-6-glucuronide) in the first 96 hours after birth 
in the TH+M group.  
We also aimed to describe the clinical course and document the clinical tolerability of 





Ethical approval to conduct the study was obtained from the Stellenbosch University 
Human Research Ethics Committee (N10/05/157), and from the management of 
Tygerberg Hospital (TBH). 
Written informed consent was obtained from the parents of all the included infants. 
Setting 
The study was conducted in the neonatal intensive care unit of TBH, a tertiary referral 
unit in Cape Town (South Africa) between March 2012 and June 2016. The service 
has 8 intensive care beds with ventilation facilities and 4 high care beds, and a total of 
124 neonatal beds. 
Study design and procedures 
Forty five infants admitted for TH were included. These were infants who met TOBY11 
study-based entry criteria for TH (at least 36 weeks gestational age, with evidence of 
perinatal compromise, and clinical and/or electrophysiological evidence of moderate 
to severe encephalopathy). The infants were selected using random computer-
generated numbers to receive either TH alone or TH+M at a morphine dose of 25 
µg/kg/h (given as morphine sulphate) from the onset of hypothermia for the duration 
of the cooling period (72 hours). Infants that did not meet the criteria for therapeutic 
hypothermia were excluded. 
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All the infants were commenced on TH within 6 hours of birth, and cooled to a rectal 
temperature of 33.5°C for a duration of 72 hours. They were then rewarmed slowly at 
a rate not exceeding 0.5°C/h.  
Infants that required additional sedative drugs for any indication received 
phenobarbitone, benzodiazepines or clonidine at attending clinicians’ discretion. 
All infants had routine monitoring of hematological (full blood count, coagulation) and 
biochemical (renal function and liver enzymes) parameters, as well as routine 
intensive care monitoring of HR, BP, O2 saturations and blood gases as indicated. 
In addition, the infants in the TH+M group had serial blood and cerebrospinal fluid 
(CSF) samples taken for measurements of morphine and metabolite (M-3-G and M-6-
G) concentrations as follows: serum at 24, 72 and 96 hours and CSF at 72 hours. 
Blood and CSF samples were centrifuged at 3500 rpm. Both serum and CSF samples 
were stored at -80 °C until analyses. 
Materials 
Morphine-d3 (1.0 mg/ml in methanol), morphine-3-β-D-glucuronide (M-3-G)  and 
morphine-6-β-D-glucuronide (M-6-G) were obtained from Toronto Research 
Chemicals (Toronto, ON Canada). These are pure compounds used to prepare the 
standards as below: 
LCMSMS Sample preparation 
Morphine calibration standards were prepared by first diluting a 1000 µg/L stock 
solution into serum (2 x dilutions). Subsequent dilutions were made with 500 µl 
standard + 500 µl blank serum. This produces the following calibration standards: 500, 
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250, 125, 62.5, 31.25, 15.63, 7.9, 3.8, 1.95 µg/L morphine + morphine metabolites in 
serum. 
The serum or CSF samples for analyses were constructed by transferring 100 µl 
serum or CSF  sample/standard + 100 µl 10 mM ammonium carbonate into 2 ml 
Eppendorf vortex wells. Of the above mixture 200 µl was transferred into an Oasis 
HLB Prime well (96 well plate). Each well was washed with 200 µl 95% water/5% 
methanol, dried under vacuum and then eluted with 250 µl 50/50 methanol/acetonitrile 
containing 5 µg/L morphine-d3. Eluates were collected in a 350 µl collection plate, 
sealed with a silicon pad and transferred to the autosampler for analysis. 
Analyses of Morphine by LC-MSMS  
A Waters Acquity ultra performance liquid chromatograph (UPLC) coupled to a Xevo 
TQ-MS mass spectrometer (MS/MS) (Waters, Milford, MA, USA) was used for high-
resolution UPLC-MS/MS analysis. Separation was achieved on an Acquity UPLC BEH 
C18 (2.1 x 100 mm; 1.7 µm particle size) column at 40 ˚C and a flow rate of 0.35 
ml/min. Data was acquired with multiple reaction monitoring (MRM) using electrospray 
positive ionization. The operating parameters used were as follows: capillary voltage, 
3.5 V; cone voltage range, 10-35 V; collision energy range, 5-40 eV; source 
temperature, 140 ˚C; desolvation temperature, 400 ˚C; desolvation gas, 800 L/h and 
cone gas, 50 L/h. An injection volume of 5 µl was used and the mobile phase consisted 
of 10 mM ammonium carbonate in water (A) and 10 mM ammonium carbonate in 25ml 
water/225 ml acetonitrile (B).  
The gradient consisted of a flow rate 0.35 ml/min, starting with 95% A to 100% B over 
5 minutes, with a 1 minute wash step at 100% B, followed by re-equilibration to initial 
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conditions over 2 minutes. Analytes were quantified using the following MRMs: 
morphine 286 ->152 and 286->165, morphine-d3 289->153, 289->165,  morphine-3-
β-D-glucuronide 462->286, .0;  morphine-6-β-D-glucuronide 462->286.  Limit of 
detection was 0.05 µg/L.  
Statistics 
GraphPad software (GraphPad Software Incorporated, La Jolla, CA, USA) was used 
for statistical analysis. Chi-square and Fisher’s exact two-tailed tests were used to 
compare categorical data, and the t-test or Mann Whitney U test were used to compare 
continuous data variables between the groups. Statistical significance was set at 
p<0.05. 
Results 
Baseline characteristics of the infants treated with TH plus morphine are shown in 
Table 7.1. During the admission, the morphine group had a lower proportion of infants 
with liver dysfunction and a significantly lower seizure burden (Table 7.2). Other 
clinical parameters were similar between the groups, with no significantly increased 
need for ventilation or hypotension requiring inotropic support in the morphine group. 
Time to discharge was not increased in the therapeutic-hypothermia-plus-morphine 
group. 
Morphine 
19/23(82.6%) infants in the TH+M group group had samples recorded for morphine 
and metabolite analyses; 12(63.2%) of them had the full set of analyses performed, 
including both serum and CSF. 
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Median concentrations and AUCs of morphine and its metabolites at 24, 72 and 96 
hours in serum and at 72 hours in CSF are depicted in Table 7.3. Individual and mean 
concentrations of morphine and metabolites in serum and CSF are depicted in Figures 
7.1-7.2. Relative mean concentrations of morphine and its metabolites between CSF 
and serum at 72 hours are shown in Table 7.4. Morphine CSF: serum concentration 
was 2.6 and 3.6 times higher than that of M-3-G and M-6-G, respectively. 
There were no differences in the mean serum and CSF concentrations of morphine 
and its metabolites between the infants with liver dysfunction and those without (Table 
7.5). 
There was no correlation between morphine serum concentrations and the two 
metabolites M-3-G and M-6-G (Spearman r correlation coefficients -0.1662 and 
0.3556, respectively), nor was there correlation was between M-3-G and M-6-G 
(Spearman r = 0.2860).  
There was positive correlation between serum metabolite to morphine ratios: M-6-G/M 
and M-3-G/M (Spearman r = 0.9654; P < 0.0001).  
Discussion 
In this study we describe the concentrations in serum and cerebrospinal fluid of 
morphine and its metabolites, morphine-3-glucuronide (M-3-G) and morphine-6-
glucuronide (M-6-G), in a cohort of infants with HIE treated with therapeutic 
hypothermia. Based on prior literature, we expected to find high concentrations of 
morphine and its metabolites during the hypothermic period due to reduced liver 
metabolic activity and renal clearance.  
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We found median serum morphine concentrations of 6.1 and 7.3 µg/L at 24 and 72 
hours, respectively, after a constant infusion at a dose of 25 µg/kg/h for 72 hours 
(Table 7.3). The serum concentrations were below 20 µg/L at all time points (Figure 
7.1). Serum concentrations of morphine required for adequate neonatal/infant 
analgesia vary widely, and have been reported to range from 4 to 125 µg/L7,9,12. The 
median AUC for serum morphine was 538 and mean 547 µg.h/L. 
These results differ from data reported in other studies on neonates with HIE treated 
with therapeutic hypothermia, with only 50% of our infants with concentrations above 
10µg /L up to 72 hours (Figure 7.1). In the majority of these studies, morphine dosage 
in excess of 10 µg/kg/h resulted in morphine serum concentrations above the 
generally accepted therapeutic range of 10-40 µg /L (up to 125 µg /L in neonates), 
with some even in the toxic range >300 µg/L7,10,13  due to reduced clearance of the 
drug. One study had a mean serum morphine AUC 32 times greater than what we 
found at 18 608 (8384)ng/h/ml7. 
There were significant differences in how morphine was administered in these studies 
compared to ours: 
Roka et al7 used a loading dose of 50-100 µg/kg, followed by an infusion adjusted 
according to clinical status up to a maximum dose of 30µg/kg/h. Favie et al10 generally 
allowed a loading dose of between 50-100 μg/kg, followed by a continuous infusion 
with doses varying between 5 and 25 μg/kg/h adjusted at physician discretion. In the 
study by Frymoyer13, the morphine dosing regimen was decided by the treating clinical 
team, with different practices between the two centres.  In one centre  the 
recommended morphine starting dose was 20 μg/kg/h via continuous intravenous 
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infusion, with a planned dose reduction to 10 μg/kg/h 24 hours after the onset of 
hypothermia treatment. At the other centre, morphine was given either at a dose of 40 
μg/kg every 6 hours or as a continuous intravenous infusion of 10-20 μg/kg/h. At both 
centres, the dose was adjusted based on assessment of clinical need (pain, 
discomfort, and shivering) and additional intermittent bolus doses of 50–100 μg/kg 
morphine could be given as determined by the treating clinical team. In contrast, 
loading doses were not administered in our study and all the infants received a 
standard dose of 25 μg/kg/h by continuous infusion from the onset of therapeutic 
hypothermia for 72 hours. The differences in dosing regimens likely played a role in 
the significantly higher concentrations achieved in these studies compared to our 
study. 
Importantly, some studies7,14 showed that infants on morphine had more complications 
such as increased need for ventilation or circulatory support and increased length of 
hospital stay without added neuroprotection. In our study we found the opposite: no 
significant increase in ventilatory or circulatory support or increased duration of 
admission.  
Morphine metabolite concentrations were also much lower than has been reported in 
literature. Neither the M-3-G nor M-6-G concentrations exceeded 50 µg/L at any time 
point, whereas in the one study where some of the infants received morphine at similar 
dosages to ours during hypothermia10 M-3-G and M-6-G concentrations reached 931 
and 211 µg/L respectively. 
Median concentrations of morphine, M-3-G and M-6-G at 72 hours in the CSF were 
all below 10 µg/L (Table 7.3). However, we have not found studies in newborns looking 
at CSF morphine and/or metabolite concentrations to determine whether these levels 
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were within acceptable therapeutic range or not. One study in older children with 
leukaemia and not subjected to hypothermia demonstrated maximum CSF 
concentrations of 16ng/ml(µg/L) and 34ng/ml of morphine (2 hours) and M-6-G (8 
hours), respectively, after a single intravenous dose of morphine15.  Due to the fact 
that our infants had HIE, received therapeutic hypothermia, and were more immature 
we might have expected higher concentrations than those demonstrated in older  
children.  
We found no correlation between morphine serum concentrations and the two 
metabolites M-3-G and M-6-G, nor between the metabolites themselves. However, we 
did find a significant positive correlation between ratios of metabolites to morphine (M-
3-G/M and M-6-G/M (Spearman r = 0.9654; P< 0.0001). This might suggest that the 
capacity for morphine glucuronidation was not saturated (taking into consideration that 
no loading dose or dose changes were made and generally higher morphine infusion 
rates were administered in our study in comparison to the other studies). Another 
factor that could possibly support this is the fact that there was no significant liver injury 
in our cohort, with very few infants with ALT >100 U/L. This would indirectly indicate 
that the metabolic activity of the liver, and hence glucuronidation, was not greatly 
affected.  
A systematic review16 of 1232 patients that included neonates from the pre-cooling 
era looked at factors that influence the ratios of morphine and its metabolites in both 
serum and CSF. They found that metabolite concentrations were increased in the 
presence of renal impairment, there was good correlation between the serum levels 
of the two metabolites regardless of clinical situation, and relative morphine CSF 
concentrations were 4 times higher than those of the metabolites. We also found that 
the relative morphine CSF penetration was higher than that of the metabolites in our 
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study, with CSF:serum concentration of morphine 2.6 and 3.6 times higher than that 
of M-3-G & M-6-G, respectively (Table 7.4). We did not find higher concentrations of 
metabolites in patients with renal impairment in our cohort (data not shown), nor did 
we find higher concentrations of morphine or metabolites in those with liver dysfunction 
(Table 7.5). This may be due to the relatively small numbers. 
Various possible reasons were considered for the different pharmacokinetics found in 
our study. 
While it is known that the risk of incorrect drug concentration is increased while 
preparing small volume infusions for neonates in the ward 17, an attempt was made to 
mitigate this risk by having a standard infusion prescription for all these infants and as 
far as possible, having a senior investigator double check all the prescriptions of 
enrolled infants. 
Another possibility considered is that of the use of expired drug. While drug storage 
conditions and controls are quite strictly enforced at TBH, in the unlikely event that this 
was the case, it would appear from the Shelf Life Extension Program program of the 
FDA18  that morphine has quite extended validity (>7 years) beyond the recorded 
expiry dates. 
The possibility that the infants were not significantly hypothermic to affect morphine 
metabolism is another consideration, but this was unlikely as we have shown our 
ability to maintain the temperature within the target range19. 
Other possible factors that could account for the unexpected results in our study are 
genetic polymorphisms affecting transport, metabolism, pharmacodynamic factors, 
etc. Studies, mainly in adult cancer and post-operative patients, have found conflicting 
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results with respect to the role of polymorphisms in response to morphine and which 
responses are clinically significant. Some have suggested that combinations rather 
than single genetic variants (e.g. OMRM1 & COMT) may be responsible for variations 
in morphine response. However, it is thought that physical factors in the patient such 
as liver or kidney dysfunction and age may have more of an influence on 
pharmacokinetics. Some drugs are thought to up- or down-regulate expression of 
some pharmacologically important gene products. Thus, variability in response 
between individuals may be due to a combination of several genetic variants and non-
genetic factors acting together20 and it is possible that this may have a role in our 
results.   
Much has been written about inter-individual and inter-/intra-ethnic differences in 
response to morphine based on variations in genes coding for receptors or 
metabolising enzymes such as the uridine diphosphate-glucuronosyltransferase-2B7 
(UGT2B7) isoenzyme. The human UGT-glucuronosyltransferase superfamily contains 
more than a dozen members with important roles in the transfer of the glucuronic acid 
group of uridine phosphoglucuronic acid to various endogenous and exogenous 
compounds and facilitating their excretion in bile or urine. Morphine is conjugated by 
the cation of Phase II enzyme UGT into morphine-3-glucuronide and morphine-6-
glucuronide. The isoenzyme UGT2B7 is the major enzyme responsible for morphine 
glucuronidation, while UGT1A1 plays a more minor role.  
Hirota described differences in UGT2B7 alleles and µ opioid receptors (MOR1) in 2 
cancer patients with differing morphine response, and also differences in UGT2B7 
alleles amongst a Japanese population21. Similarly, Zhang found different variants of 
UGT1A1 among different groups within a Chinese population, which resulted in 
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different glucuronidation activity22. On the other hand, two studies found racial 
differences in UGT2B7 and UGT1A1 haplotypes among African-American, Caucasian 
and Japanese groups in both paediatric and adult populations, although there was not 
always direct association with morphine clearance23,24. A study looking at long-term 
effects of morphine in preterm infants, found that the effects were influenced by 
genetic variants in the metabolic pathway (particularly UGT1A1 and COMT) but that 
there was a complex interaction between these genetic and clinical factors that 
influenced outcome25. 
All these studies support the possibility of a significant contribution of genetic 
polymorphisms (in particular of the UGT2B7 isoenzyme), probably in combination with 
other clinical factors, in accounting for the different findings in our study. This deserves 
further exploration in future studies. 
Finally, despite the differences in the pharmacokinetic data found in our study, it is 
reasonable to accept that this simple validated method, that includes solid-phase 
extraction, enabled us to quantify high recoveries of morphine and its metabolites in 
plasma and CSF samples.   
Conclusion 
We found that continuous morphine infusion at a dose of 25 µg/kg/h for 72 hours was 
tolerated well in this cohort of infants treated with therapeutic hypothermia, and did not 
result in serum concentrations that would be considered toxic. Serum concentrations 
were within or below the generally accepted therapeutic range in the first 72 hours. 
We also demonstrated that morphine penetrates the CSF in higher concentrations 
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Table 7.1: Baseline characteristics of patients in TH+M group 
 Hypothermia + Morphine  
(Group 1)                    N=23  
Maternal age, mean (SD), years 26.1 (6.2) 
Primiparity, n (%) 13 (56.5) 
Inborn, n (%) 11 (47.8) 
Gestational age, mean (SD), weeks 38.86 (1.46) 
Birthweight, mean (SD), grams 3263 (646) 
Male, n (%) 15 
Head circumference, mean (SD), cm 35.1 (1.9) 
Sentinel event*, n (%) 7 (30.4) 
Apgar at 5 minutes <5, n (%) 7 (30.4) 
pH within 1st hour <7, n (%) 11 (47.8) 
Time to admission, h 
mean (SD) 
4.4 (1.3) 
Time to target (33.5°C), h 
mean (SD) 
7.1 (2.8) 
HIE 2#, n (%) 21 (91.3) 
HIE 3#, n (%)  2 (8.7) 
TH+M: therapeutic hypothermia plus morphine 
* Sentinel event: uterine rupture, abruptio placentae, cord prolapse, acute exsanguination  




Table 7.2: Clinical course and complications in the two treatment groups 








Ventilated, n (%) 16 (69.6) 11 (50) 0.231  
Duration of ventilation, days 
Mean (SD) 
4.36 (4.03) 2.86 (3.71) 0.206 
MAS/PPHN, n (%) 5 (21.7) 4 (18.2) 1.000 
Inotropic support, n (%) 6 (26.1) 4 (18.2) 0.722 
Coagulation abnormality, n (%) 11 (47.8) 13 (59.1) 0.554 
Thrombocytopaenia, n (%) 11 (47.8) 8 (36.4) 0.550 
Culture-positive infection, n (%) 4 (17.4) 1 (4.5) 0.346 
NEC, n (%) 1 (4.3) 1 (4.5) 1.000 
Renal dysfunction, n (%) * 5 (21.7) 8 (36.4) 0.337 
Creatinine, mean (SD) 57.77 (30.57) 62.23 (30.18) 0.376 
Creatinine, median (range) 55 (12-201) 59.5 (14-174) 0.295 
Liver dysfunction, n (%) * 2 (8.7) 8 (36.4) 0.035 
ALT, mean (SD) 54.69 (62.81)  77.38 (92.67) 0.133 
ALT, median (range) 28 (11-319) 37 (13-452) 0.119 
Hypoglycaemia, n (%) # 9 (39.1) 8 (36.4) 1.000 
Hyperglycaemia, n (%) 4 (17.4) 7 (31.8) 0.314 
Significant seizure burden, n (%)$ 3 (13.0%) 13 (59.1%) 0.002 
LOS, days - mean (SD) 12.7 (5.9) 11.9 (6.9) 0.699 
*Transient, not severe. ; # Both early transient & requiring treatment (only 1 required treatment, in TH only group).  
## Both early transient & requiring treatment (4 in TH only and 1 in TH+M group needed treatment) 
$ needing 2 or more anti- epileptic drugs 
MAS: meconium aspiration syndrome; PPHN: persistent pulmonary hypertension of the newborn; NEC: necrotising enterocolitis. 
ALT: alanine transaminase. LOS: length of stay 
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Table 7.3: Serum and CSF concentrations of morphine and metabolites in whole 
group 
 Serum – median (range), µg/L CSF – median (range), µg/L 
Morphine 24h 6.05 (1.20-16.26)  
Morphine 72h 7.27 (1.91-14.10) 5.09 (1.39-8.65) 
Morphine 96h 1.17 (0.21-7.30)  
AUC 537.5 (112.8-1053.0) 201.6 (45.9-285.5) 
M-3-G 24h  9.35 (2.07-34.40)  
M-3-G 72h  10.88 (3.99-49.45) 4.08 (0.79-8.71) 
M-3-G 96h 4.60 (0.66-18.10)  
AUC 887.2 (164.1-3090.0) 134.6 (26.1-287.4) 
M-6-G 24h 1.97 (0.40-8.46)  
M-6-G 72h 2.63 (0.91-13.99) 0.65 (0.13-1.48) 
M-6-G 96h 1.12 (0.19-4.27)  
AUC 188.9 (35.0-832.7) 21.5 (4.3-48.8) 
AUC: area under curve; M-3-G: morphine-3-glucuronide; M-6-G: morphine-6-glucuronide 
Table 7.4: Relative CSF penetration of morphine and metabolites 
 Ratio of mean 
concentrations 
CSF:serum morphine 0.64 
CSF:serum M-3-G 0.25 
CSF:serum M-6-G 0.18 
M-3-G: morphine-3-glucuronide; M-6-G: morphine-6-glucuronide 
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Table 7.5: Drug levels in those with or without liver dysfunction 
Sample Liver dysfunction 
Mean (SD)                          
N=2 
No liver dysfunction 




morphine 7.490 (6.364) 7.004 (3.923) 0.876  
72h serum 
morphine 8.370 (6.718) 8.109 (3.662) 0.930 
96h serum 
morphine 3.160 (3.338) 2.425 (2.382) 0.695  
72h CSF morphine 4.780 (3.734) 5.270 (2.571) 0.818 
24h serum M-3-G 14.905 (7.856) 12.985 (9.830) 0.795 
72h serum M-3-G 11.905 (8.577) 15.063 (12.324) 0.733 
96h serum M-3-G 5.255 (4.716) 6.092 (5.421) 0.838 
72h CSF M-3-G 5.145 (5.042) 3.410 (2.287) 0.414 
24h serum M-6-G 3.410 (2.051) 2.977 (2.304) 0.803 
72h serum M-6-G 2.685 (1.676) 3.569 (3.222) 0.713 
96h serum M-6-G 1.325 (1.195) 1.529 (1.363) 0.843 
72h CSF M-6-G 0.9150(0.799) 0.557 (0.350) 0.282 
CSF: cerebrospinal fluid; M-3-G: morphine-3-glucuronide; M-6-G: morphine-6- glucuronide  
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Figure 7.1: Individual and mean serum concentrations of morphine and 
metabolites 
 






In chapters 1 and 2, we discussed the importance of identifying and selecting infants 
for neuroprotective therapies correctly, and having simple tools for achieving this goal. 
This study assessing the role of nucleated red blood cells in predicting disease severity 
and outcome in HIE presents the output from a masters thesis that I conceptualized 
and supervised. 
Nucleated RBCs in neonates with HIE treated with hypothermia  
Lunga Mfingwana1,2, Jeanetta Van Zyl2, Johan Smith1,2, Mary Rutherford1,3, 
Gugulabatembunamahlubi Tenjiwe Jabulile Kali1,2 
6. Department of Paediatrics and Child Health, Faculty of Medicine and Health 
Sciences, Stellenbosch University, Cape Town, South Africa 
7. Tygerberg Children’s Hospital, Cape Town, South Africa 
8. Division of Bioengineering and Imaging Sciences, Department of Perinatal 
Imaging and Health, Centre for Developing Brain, St Thomas’ Hospital King’s 
College, London, UK  
Introduction  
Neonatal hypoxic ischaemic encephalopathy (HIE) or perinatal asphyxia is a leading 
cause of term neonatal death  world wide with a higher incidence in middle and low 
income settings (1). To date therapeutic hypothermia (TH) is the only interventional 
strategy internationally accepted as effective in neonatal HIE(2). We have previously 
demonstrated its safety and efficacy in a sub Saharan setting (3). The majority of high 
risk neonates present with low Apgar scores at delivery and would require active 
resuscitation. Current clinical practice would recommend clinical assessment of the 
neonate, combined with evidence of fetal distress and hypoxia from both 
cardiotocography and  umbilical cord pH to confirm a diagnosis of probable HIE . 
Active TH is then started as soon as possible, usually following confirmation of 
abnormal brain activity on cerebral  function  monitoring (CFM), if available(4). In low 
and middle income settings, CTG facilities, blood gas machines and CFM equipment 
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may not be universally available, particularly at district level hospitals in South Africa 
where a significant number of asphyxiated infants are born. 
There is a need,  1therefore, for simple markers that can reliably identify at risk infants 
and especially those asphyxiated infants that are most likely to respond to treatment.  
There are several published studies reporting an  association between the number of 
neonatal nucleated red blood cells (NRBC) and perinatal asphyxia (5); demonstrating  
a significant association between absence of fetal heart rate accelerations and 
elevated NRBC in asphyxiated neonates(6), and a correlation with increased NRBC 
and degree of acidosis and low Apgar scores (7). Tungalag et al found that increased 
cord blood NRBC in asphyxiated infants predicted the occurrence and severity of HIE, 
proposing its use as an inexpensive assessment tool in settings where there are no 
facilities for blood pH measurements (8). 
A raised NRBC count in the umbilical cord blood, combined with other markers such 
as lactate, have also been used to predict the severity of HIE and neurodevelopmental 
outcome in infants not treated with TH (9).  
In the TH era, Li and co-workers concluded that NRBC counts could predict 
neurological outcomes at 2 years in cooled and non-cooled asphyxiated neonates, 
albeit not as well as a brain MRI at 2 weeks post delivery (10)  
In utero subacute or chronic hypoxia stimulates fetal erythropoiesis, resulting in an 
increased release of immature red blood cells (NRBC) into the fetal circulation with 
reports suggesting that it takes 4-5h from onset of hypoxia to increase levels of 
erythropoietin and then approximately 24h for NRBCs to appear on a peripheral film 
(11). However, acute stress can lead to release of marrow stores of NRBCs in a 
shorter period (12). NRBC, in combination with other biomarkers, may be useful in 
identifying those infants where there is no clear sentinel event (13). 
Although NRBC can be found in neonatal blood following low risk pregnancy and 
delivery, the NRBC/100 white blood cells (WBC) seldom exceeds 10/100 WBC (5). 
There are however several factors that appear to increase NRBC including not only  
asphyxia, but also prematurity, Rh-sensitization, maternal diabetes mellitus and fetal 
growth restriction (8,14).  
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Phelan et al described NRBC > 10/100WBC as a marker for fetal asphyxia (15). Li et 
al concluded that both the NRBC count per 100WBC and absolute NRBC taken within 
6 hours in asphyxiated infants had a significant association with abnormal 2-week MRI 
findings (P = 0.006) and 2-year neurodevelopmental sequelae (P = 0.021)  , in both 
hypothermic and normothermic infants. The association was stronger for cerebral 
injury on MRI (10).  
Most hospitals in South Africa, including district hospitals, are attached to a functional 
NHLS laboratory service. Access to FBC is therefore a widely available special 
investigation. However, the ability of hospitals at different levels to identify NRBC 
varies with some machines only having the ability to identify the presence of NRBC 
and requiring referral of the peripheral smear to the main tertiary laboratory for analysis 
and to quantify the NRBC. While ability to quantify NRBC should pose no additional 
demand on resources, the turn-around time may vary from a minimum of 30 minutes 
to 1 hour to a few hours depending on these logistical factors. 
This current study sought to determine whether NRBC could be used to predict the 
degree of severity in hypoxic ischemic encephalopathy in full term neonates in a 
tertiary referral hospital in South Africa, and whether NRBC levels could predict long-
term neurodevelopmental outcome in HIE neonates treated with therapeutic 
hypothermia in order to identify those who might benefit from additional 
neuroprotection.  
Specific aims were, therefore:  
• To report the NRBC count in the first 6 hours in a cohort of neonates  with HIE 
treated with therapeutic hypothermia (TH) at TBH between 2008 and 2011 
• To determine the association between NRBC counts and severity of HIE as 
determined by the Thompson encephalopathy score 
• To determine the association between NRBC counts and neurodevelopmental 




This was a retrospective sub-study within a larger study investigating therapeutic 
hypothermia in neonates suffering from hypoxic ischemic encephalopathy 
[N10/05/157]  
The study was conducted at Tygerberg Hospital (TBH), a tertiary health facility in Cape 
Town which serves the eastern part of Cape Town metropole as well as the northern 
and eastern rural districts of the Western Cape.  
All neonates with moderate to severe hypoxic ischemic encephalopathy born in 
Tygerberg Hospital or referred from surrounding districts that meet criteria for 
therapeutic hypothermia are admitted to the neonatal intensive care unit (NICU).   
Infants born at TBH or referring hospitals over a three year period between November 
2008 and November 2011, that met cooling criteria (as below) for the treatment of HIE 
and were admitted to TBH NICU, were included in the study. 
Inclusion criteria based on TBH cooling criteria for neonates diagnosed with HIE were: 
Infants of ≥36 completed weeks gestation with at least one of the following:  
Apgar ≤7 at 10 minutes of age; continued need for resuscitation, including 
endotracheal intubation or mask ventilation at 10 minutes of age; acidosis within 60 
minutes of birth, defined as any occurrence of umbilical cord, arterial or capillary blood 
pH <7 or base deficit ≥ 16 within 60 minutes of birth.  
Infants that met the above criteria were further assessed for neurological abnormality 
using a combination of modified Sarnat criteria and a Thompson score of ≥10 (16) or 
presence of seizures by the attending physician. 
Exclusion criteria included those neonates that did not meet the above minimal 
requirements and would not normally be cooled: presence of  major congenital 
abnormalities, prematurity (<37 weeks gestation) and severe growth restriction 
(birthweight <1.8kg), over 6 hours after delivery at time of assessment, presence of 




All patients admitted for therapeutic cooling were treated according to a set protocol 
(3). The treatment included the following:  
Patients were cooled using the total body hypothermia for 72 hours using the 
Tecotherm TSmed 200 N system, and then re-warmed slowly over a minum of  6 
hours.  
Blood samples, including those for the determination of NRBC count, were taken 
within the first hour of admission which was within 6 hours of birth, and repeated 
according to the cooling protocol.  
Amplitude integrated electro-encephalogram (aEEG), when available, was applied to 
monitor brain activity and seizures, and seizures were treated using the TBH neonatal 
seizure protocol.  
Cranial ultrasound imaging was done on all infants within 72 hours of birth. 
The Thompson score (16) assessing the severity of HIE was performed on admission 
and repeated every 24 hours. Encephalopathy grade was assigned based on 
maximum score after admission to NICU.  
The infants were discharged to the neonatal ward following successful therapeutic 
hypothermia and re-warming, and subsequent to hospital discharge followed up to 1 
year of age at the neonatal high-risk clinic where neurodevelopmental assessments 
were performed by a single neurodevelopmental specialist.  
A retrospective review of the clinical notes on Enterprise Content Management (ECM) 
database and cooling data booklets used routinely for all cooled neonates was 
performed.  
A database with clinical information of these patients from a previous study 
(N10/05/157) was also accessed and compared with collected data for consistency. 
Clinical data of participants is summarised in Table 8.1. 
To determine individual NRBC data, the NHLS database system TrackCare (DISA) 
was accessed. Blood samples were analysed retrospectively. 
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An automated system was used for detecting presence of and a threshold nucleated 
red blood cell level of 30/100 WBC, using the Siemens Advia machine. If the initial 
machine report was less than 30 NRBC/100 WBC, quantification of the exact number 
was not performed. If ≥30 NRBC/100 WBC were reported, a smear was done by the 
haematologist for further manual quantification and description of the NRBC.  This is 
the current standard protocol in the NHLS laboratory at TBH.  
The first NRBC samples taken at the time of admission for cooling were used and 
compared with the first Thompson score subsequent to admission to the NICU (<6 
hours of age). 
Long term neurological assessment:  
A single developmental specialist using the Bayley Scales of Infant Development Third 
Edition Screening Test (Bayley-111® Screening Test) reviewed all recruited patients 
in the neonatal high-risk clinic at 3 months and 12 months of age. The 12-month data 
were used in this study. 
Statistical analysis: 
All the data considered from the laboratory and ECM was transferred to Excel spread 
sheets. Data variables were allocated numerical codes and exported to statistical 
software (ANOVA and NCSS 12 data [NCSS LLC, 329 North East, Kaysville, Utah, 
USA] analysis software) for further analysis.  
Data was presented as means (±SD). The quantitative variables were compared using 
Student’s t-test and analysis of variance (ANOVA). 
The association between NRBC proportion and the following outcomes were 
determined: severity of HIE as determined by maximum Thompson score, neonatal 
death (short term) and the long-term neurological outcome.  
Bivariate data were assessed using Pearson’s chi square test and Fisher’s test for 
categorical variables. P-value < 0.05 was considered statistically significant. 
Ethical approval was obtained from the Human Research Ethics Committee (HREC) 
of Stellenbosch University. As this was a retrospective analysis of routinely collected 
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data for which ethical permission had previously been obtained and no new patient 
interventions were to be performed, a waiver of individual informed consent was 
granted by Stellenbosch University’s HREC. [S17/03/066].  Permission to conduct the 
study was also granted by the management of TBH. 
Results 
A total of 100 patient folders from 1st November 2008 and 30th November 2011 were 
reviewed for inclusion into the study. Of the total 100 files accessed, 25 were excluded 
due to significant missing data (those patients that were excluded either did not have 
a valid NRBC done within 6 hours of life/at commencement of cooling, no clear HIE 
score documented within 6 hours and no follow up information was available). The 
remaining 75 infants constituted the study cohort.    
The study cohort was categorized according to their Thompson score into the following 
clinical categories: mild HIE (n=42 [56%]), moderate HIE (n=20 [26.7%]) and severe 
HIE (n=13 [17.3%]). (Figure. 8.1) 
Figure 8.1: Flow chart illustrating patient selection and outcome according to 
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Table 8.1. Clinical characteristics of cohort 
Clinical Data N-75 
Maternal age (mean ± SD), n=73 25.9 (±7.3) 
Primiparity; n (%) 24 (32) 
HIV positive; n (%) 13 (17) 
Male; n (%) 46 (61) 
Gestational age; weeks (mean ± SD)  38.6 (± 4.8) 
Birth weight; grams (mean ± SD) 3117 (±610) 
Apgar score 5’; (mean ± SD) 4.7 (±1.6) 
Mild HIE; n (%) 42 (56) 
Moderate HIE; n (%) 20 (26.7) 
Severe HIE; n (%) 13 (17.3) 
Neonatal Deaths; n (%) 9 (12) 
 
The mean gestation and birth weight was 38.6 (±4.8) weeks and 3117(±610) grams, 
respectively. There was no statistically significant association between the gestational 
age and birth weight, and the degree of HIE (Figures 8.2 and 8.3).  
Infants with a gestational age greater than 40 weeks ccounted for 12% (n=9/75) of the 
cohort and 3 infants had a weight greater than 4000 grams. Infants with fetal growth 
restriction were excluded.  
24 (32%) infants were inborn, while 51 (68% ) were referred in for treatment. There 
was no statistical difference in the severity of encephalopathy between the inborn 
infants and the outborn infants.   
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Figure 8.2: The relationship between the birth weight and the severity of hypoxic 
ischemic encephalopathy. 
 
Figure 8.3: The relationship between gestational age and severity of hypoxic 
ischemic encephalopathy. 
 
The categorization of the severity of HIE (mild ≤ 10, moderate 11-14, severe ≥15) in 
the inborn infants was as follows: mild HIE 50% (12/24), moderate HIE 33.3% (8/24) 
and severe HIE 16.7% (4/24); and in those that were referred (outborn) for cooling: 
mild HIE 58.8% (n=30/51); moderate HIE 23.5% (n=12/51) and severe HIE 17.7% 
(n=9/51). There was no statistically significant difference between the proportions of 
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moderate-severe HIE in the inborn and outborn infants (inborn 12/24 vs outborn 21/51; 
P=0.473), (Figure 8.4). 
Figure 8.4. Comparing the severity of hypoxic ischemic encephalopathy in 
inborn infants to out-born infants.   
 
All the patients (n=75) had full blood counts (FBC) done within the stipulated first 6 
hours from delivery. NRBC were detected in 39 (52%) of the samples. The distribution 
of the NRBC in the 75 samples shown in Table 8.2.  On days 2 and 3, only 23 and 11 
patients had reported NRBCs, respectively.   
50% of neonates with mild HIE had no documented NRBC, compared with 55 % of 
neonates with moderate HIE and 31% of those with severe HIE. There was no 
significant association between the category of NRBC and HIE severity (p=0.265). 
The median NRBC value in the infants ≥ 30/100 was 83 (37 - 141). 
Table 8.2. Distribution of NRBC in the different HIE categories. 
 Total  mild HIE  
n=42 




NRBC = 0 n = 36 21/42 (50%) 11/20 (55%) 4/13 (30.8%) 
NRBC = 1-29 n = 31 18/42 (42.9%) 5/20 (25%) 8/13 (61.5%) 
NRBC = ≥ 30 n = 8 3/42 (7.1%) 4/20 (20%) 1/13 (7.7%) 
Total with NRBC N = 39 21/42 (50%) 9/20 (45%) 9/13 (69.2%) 
NRBC ≥ 30 
Median (range) 
N =8   52 (37 – 72) 97.5 (63 – 108) * 141 
NRBC: nucleated red blood cells/100 white blood cells. HIE: hypoxic ischemic encephalopathy  













When comparing the long-term outcome of the children when evaluated at 12 months, 
increased NRBC in the first 6 hours after delivery was associated with a poorer 
outcome. Those children with NRBC counts of ≥30/100 soon after birth had an 
increased likelihood of having cerebrtal palsy (CP) or impaired neurodevelopment at 
long-term follow up (P=0.013; Odds ratio 20.17; 95% CI 1.017 – 399.6); on the other 
hand, they were likely to be normal at 1 year if the NRBC count was <30/100 [Table 
8.3].  
Table 8.3. Association of NRBC with the grading of HIE, the short term and long 
term outcomes  
HIE: hypoxic ischaemic encephalopathy. NDD: neurodevelopmental delay. CP: cerebral palsy.  
 
Similarly, infants that did not survive the initial admission for TH in the neonatal period 
were more likely to have NRBC ≥30/100 soon after birth when compared to those that 
survived (P=0.008; Odds ratio 9.40; 95% CI 1.7791 to 49.6649) (Table 8.3). In contrast 
to this there was no significant association between death and the severity of HIE 
(P=0.359).  
The baseline characteristics and outcome of the 25 excluded patients did not differ 
significantly from those included in the analysis (Table 8.4). Ten of these infants had 
NRBC done but no outcome information; 15 had outcome information available (but 
no HIE grading)– 7 died, 4 had cerebral palsy/neurodevelopmental impairment and 4 
were normal. 2/11 (18%) with known poor outcome had NRBC >30.  
 NRBC<30 NRBC ≥30 Test P=value 
Mild HIE 39/67 (58.2%)    3/8 (37.5%) Chi-square  
Mod/severe HIE 28/67 (41.8%) 5/8 (62.5%) Chi-square 0.265 
NDD/CP 14/46 (30.4%) 4/4 (100%) Fischer  
Normal 32/46 (69.6%) 0/4 (0%) Fischer 0.013 
Alive (incl NDD) 47/52 (90.4%) 4/8 (50%) Chi-square  
Died 5/52 (9.6%) 4/8 (50%) Chi-square 0.008 
Inborn 18/67 (26.9%) 6/8 (75%) Chi-square  
Outborn 49/67 (73.1%) 2/8 (25%) Chi-square 0.005 
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Table 8.4: Comparison of included and excluded patients 







Primiparity; n (%) 24 (32) 13 (52%)  0.095 
HIV positive; n (%) 13 (17.3) 5 (20%)  0.769 
Male; n (%) 46 (61.3) 10 (40%)  0.102 
Gestational age; 
weeks (mean± SD) 
38.6 (± 4.8) 39 (±1,9)  0.656 
Birth weight; grams 
(mean ±SD) 
3117 (±610) 3089 (±495)  0.820 
Apgar score 5’; 
(mean ± SD) 
4.7 (±1.6)  4.8 (±2.0)  0.821 
Neonatal Deaths; n 
(%) 
9 (12)  7 (28)  0.111 
 CP/NPP; n (%)  18/50 (36)  4/8 (50)  0.462 
Discussion 
In this study we have demonstrated a significant relationship between an early 
increase of NRBC in asphyxiated infants treated with TH, and both short-term 
(neonatal death) and long-term outcome (cerebral palsy/neurodevelopmental delay). 
We also found an association between low NRBC (<30/100 WBC) and normal 
outcome at 1 year. However, we found no significant relationship between early 
increase in NRBC and either HIE severity or Apgar score. The lack of significant 
association with HIE severity may be related to the timing of clinical assessment, as it 
is known that HIE is an evolving process in the early stages. 
Several studies have postulated an increase in NRBC in infants with birth asphyxia. 
Boskabadi et al found a significant relationship between increased NRBC and infant 
mortality and morbidity (short-term and long-term outcomes). Among 36 infants who 
had HIE in their study 16 had adverse outcomes, of whom 10 demised within a month 
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and 6 developed neurodevelopmental sequelae.  They highlighted that the infants with 
adverse outcomes had significantly increased NRBC/100 WBC [18.63 (±16.63) vs 
3.87 (±5.06), p<0.001] compared to those with favourable outcome (17).  
The significance of NRBC in asphyxia has been defined both in terms of NRBC/100 
WBC and absolute NRBC count. Perrone et al defined the decreasing physiological 
nature of absolute NRBC in relation to gestation and fetal weight, and the normal 
reference ranges of absolute NRBC in term and preterm infants (18).  
Phellan et al described NRBC > 10/100WBC as a marker for fetal asphyxia (15). 
Jingang Li et al concluded that both the NRBC count per 100 WBC and absolute 
NRBC taken within 6 hours in asphyxiated infants had a significant predictive value as 
a marker for abnormal MRI findings (p = 0.006) and 2-year neurodevelopmental 
impairment (p = 0.021)(10).  
We had set out to test whether in a low resource setting such as South Africa, and 
where a majority of infants are referred in for cooling, raised NRBC could be a useful 
marker for those infants that would develop moderate-severe HIE and qualify for 
cooling and those that would go on to have poor outcome. 
In our study 9 patients demised. A larger proportion [4/8 (50%)] of infants with NRBC  
≥30/100 WBC died compared to those with NRBC <30/100 WBC [5/52 (9.6%)]; 
P=0.008. This outcome from this study further affirms available literature, that the 
higher the NRBC the more severe the short-term adverse outcome, including when 
early onset seizures are used as a marker of neurological injury (19)  
In our study we had a total of 18 infants that developed neurodevelopmental sequelae, 
while 15 were lost to follow up. Of the 18 with neurodevelopmental impairment,  
4/4(100%) had NRBC ≥30/100 WBC and 14/46 (30%) had NRBC <30/100 WBC; P = 
0.013. The infants with no follow up did not differ from those whose outcome was 
known (Table 8.5). Our data were consistent with previously published literature that 
NRBC can be used as a surrogate marker of birth asphyxia and predictor of long term 
neurological outcome.  
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Table 8.5: Baseline characteristics of infants with known and unknown 
outcomes  






Primiparity; n (%) 47 (78.3) 10 (66.7) 0.824 
HIV positive; n (%) 11(18.3) 3 (20) 1.000 
Male; n (%) 36 (60) 8 (53) 0.903 
Gestational age; 
weeks (mean± SD) 
38.3 (±5.3) 39.7 (±1.2) 0.187 
Birth weight; grams 
(mean ±SD) 
3120 (±643) 3092 (±458) 0.842 
Apgar score 5’; 
(mean ± SD) 
4.5 (±1.6) 5.4 (±1.7) 0.078 
Mild HIE; n (%) 35 (58.3) 8 (53.3) 0.854 
Moderate HIE; n (%) 13 (21.7) 6 (40) 0.439 
Severe HIE; n (%) 12 (20) 1 (6.7) 0.501 
In 1953 Apgar et al published an article proposing a clinical method of assessing 
newborn infants. Subsequent research on the value of Apgar score has exposed the 
limitations of this clinical method in assessing asphyxiated infants. The ACOG 
discussion document (2015) further suggests that it is inappropriate to use the Apgar 
score to establish the diagnosis of asphyxia as it has a low predictive value for 
mortality and/or neurological outcome (20). In our study we found this to be consistent 
with available literature. There was a weak correlation between 5-minute Apgar score 
and HIE severity (r =0.0203). 
In our current study we could not further stratify and describe the range and pattern of 
NRBC in asphyxiated infants. This is largely due to the post hoc nature of the study, 
where we could not pre-specify how we required the NRBC to be analysed. The 
current practice at Tygerberg NHLS is to only quantify NRBC ≥30 /100 WBC count. 
This current practice and policy is governed by the fact that there is no available local 
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literature that encourages further quantification of NRBC <30/100WBC count as 
contributing to clinical care. 
Weaknesses and strengths 
The strength of our study was that data on cooled infants was collected prospectively, 
and all infants were routinely followed up for 1 year by one experienced 
neurodevelopmental expert. Their outcomes were assessed using a standardized 
neurodevelopmental assessment tool (Bayley Scales of Infant Development Third 
Edition Screening Test [Bayley-111® Screening Test]). 
Our study contributes to local knowledge and the growing interest of the potential 
association between NRBC, birth asphyxia and short- and long-term outcomes. To our 
knowledge, it is the first such study to be conducted in the sub-Saharan region.    
A limitation of the study was that we could not answer the primary question of the 
study to the extent envisaged, because prospectively collected data was 
retrospectively analyzed and the NHLS laboratory were not analyzing NRBC <30/100 
WBC at the time the study was conducted. We also could not look systematically at 
serial measures of NRBC in order to understand the relationship with the perceived 
injurious process.  
The study is further limited as 25% of the selected study population did not meet the 
inclusion criteria, as either the NRBC count or the 12-month neurological development 
were not determined. 
Conclusion 
This study showed that NRBC ≥30/100 WBC had a significant correlation with early 
mortality and neurodevelopmental impairment at 1 year of age in this cohort. To gain 
a better understanding of the association between NRBC and HIE in the era of cooling 
in our local setting, there is a need for a larger multi-center study. This large 
multicentre study should focus on describing normal term infant NRBC in 
uncomplicated pregnancies and seek to further delineate the association of NRBC 
with clinical outcomes before it can be applied to select patients for neuroprotective 
therapies.   
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Neonatal encephalopathy following intrapartum events accounts for 23% of infant 
mortality worldwide, with 96% of cases occurring in low-middle income countries 
(LMIC). The highest mortality is found in low income countries and highest disability 
in middle income countries where there may be inadequate rather than non-existent 
neonatal intensive care (1). Neuroprotective therapies are therefore most urgently 
needed in these settings if we are to improve newborn and child survival and 
development (2). 
Therapeutic hypothermia, the only currently proven treatment for HIE, has been mainly 
studied in settings that are different from those of LMIC where resource capacity varies 
widely. Concerns about the applicability of TH in these settings are based largely on 
data from a very low-income setting which showed increased mortality in cooled 
infants (3). There were also concerns about converting mortality to increased survival 
with disability, resulting in even greater burden for low resource settings. 
What this work has shown 
TH (or cooling) is feasible in a middle-income country when applied within a strict 
protocol similar to those used in the large published trials, and in an intensive care 
setting where ventilation facilities are available. Significant proportions of our patients 
in both cohorts (34% retrospective, 60% prospective) required ventilation. 
TH can be optimized by more training in various aspects such as neurological 
assessment in order to select the most appropriate patients. 
It may be possible to use simple blood tests, such a measurement of NRBC counts, 
to aid in patient selection. 
There is a need for development of less costly equipment for both treatment and 
selection of patients for treatment. Servo-controlled cooling systems achieve better 
temperature stability and require less nursing input, but currently available devices are 
generally quite expensive. However, while the cheaper low technology methods of 
cooling tend to be more labour-intensive (which can be a challenge where 
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nurse:patient ratios are low), they have been shown in a meta-analysis including 
studies from low resource countries to be as effective in improving outcomes as the 
high technology methods when used in an intensive care environment (4). This 
highlights the fact that it is the close monitoring and maintaining the temperatures 
within target range that have a greater significance than the actual device used, and 
absence of high technology devices should not result in deserving infants being 
deprived of this beneficial therapy.  
Our patients did not have more complications compared to the patients studied in high 
income settings. In particular, we were able to show that the patients in these cohorts 
did not have higher rates of infection than those in high income countries, with culture 
confirmed infection rates of 8-11% in the 2 cohorts. This is relevant because there has 
been a concern that a presumed higher prevalence of infection in LMIC may make TH 
less effective due to sensitization of the brain by inflammation. Our results are in 
keeping with literature from Uganda and India, where they showed a prevalence of 
infection of <10% in encephalopathic infants, similar to rates in high income countries 
where the cooling trials were performed (5,6). 
Outcomes in our cohorts were good, with the majority (>80%) of patients surviving 
without major neurodevelopmental impairment. This is in contrast with a meta- 
analysis of TH in LMIC, which showed no beneficial effect of TH and suggested that it 
should not be offered in these settings until more trials are performed (7). Some of the 
factors that may have contributed to this negative treatment effect included lack of 
ventilation and monitoring facilities and no sedation in many infants. Most of the trials 
in this study also did not have long-term outcome data. A large meta regression 
analysis including infants from low resource settings showed a reduction in mortality 
following TH, which was not influenced by the gross domestic product of the country 
where it was applied (8). It would be of interest to compare the BSID-III scores of our 
normal survivors with those of a normal local cohort in order to fully assess the impact 
of the neuroprotective therapies on neurodevelopment in our setting. 
Our data showed that morphine co-treatment may augment the neuroprotective 
effects of TH, and resulted in reduced seizures and liver dysfunction in the randomized 
trial. It did not cause increased need for ventilation, inotropic support or prolonged 
hospital stay as shown in previous studies (9,10). The lack of significant effect on the 
outcome at 18 months may be related to the small sample size, and would need to be 
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re-tested in a larger trial as there was a trend towards improved survival with normal 
outcome. The significance of lower liver dysfunction in relation to possible better 
outcome needs further exploration. One aspect that could be pursued is whether this 
could be related to levels of ammonia, which is thought to have an effect on cellular 
glutamate concentrations and neurotransmitter signaling resulting in neural cell 
damage (11). 
We showed that morphine enters the brain (CSF) well, and does so better than its 
metabolites. We did not demonstrate toxic concentrations at the administered dose of 
25µg/kg/h. The serum concentrations were much lower than has been found in 
literature at doses exceeding 10µg/kg/h with TH (9,12). This could be on the basis of 
a combination of genetic polymorphisms and non-genetic factors that may be unique 
to our cohort. 
Tools 
We have shown that both clinical (Thompson HIE score) and neurophysiological tools 
(aEEG) are useful for selecting patients for treatment and predicting outcome. This is 
helpful in settings where costs are a major factor, as shown in the study by Biselele 
(13). Their predictive ability assists in directing care and utilising limited resources 
optimally. 
The advantages of aEEG are that it is a more objective tool for continuous assessment 
of brain activity, which can also be sent for a second opinion particularly by more 
inexperienced staff. 
While MRI in the first few weeks after birth is the optimal imaging modality for 
assessing brain injury and predicting specific outcome, ultrasound is emerging as a 
promising substitute where MRI is unavailable if the correct scanning protocols and 
equipment are used (14,15). In our prospective cohort, severe CUS abnormalities 
were predictive of abnormal outcome. 
Where MRI is available, it can have an important role in assessing newer 
neuroprotective therapies. In our cohorts, we could show that in those infants that were 




The loss of aEEG recordings in the prospective cohort meant that they could not be 
evaluated to confirm their predictive ability, and assess the effect of morphine on the 
predictive ability. 
Follow up is an ongoing challenge in this setting with 33% and 16% of the retrospective 
and prospective cohorts, respectively, lost to follow up. This is a common problem in 
similar settings, with a follow up rate of 29% described in another South African study 
(16) and creative solutions are needed to assess outcomes of therapies in these 
situations. These could include adaptation and validation of available developmental 
screening tools such as the Ages and Stages Questionnaire (17) for administration 
telephonically. However, although most studies recommend follow up to a minimum 
of 18 months to assess the effects of interventions on developmental outcomes, in our 
prospective cohort there were similar proportions of normal (84%) and abnormal 
(16%) development in those infants that were assessed at 12 and 18 month 
points. This suggests that in settings where follow up is difficult, aiming for a 
minimum follow up duration of 12 months may be reasonable.
Limited access to MRI meant that infants could not all be imaged in the first 3 weeks 
as planned. Many infants had to be re-admitted for the scan. This contributed to the 
loss to follow rate as some did not return. Having early MRI on all the infants would 
have assisted in inferring outcome even in those that did not attend follow up. New 
technologies are constantly being developed, such as low field mobile MRI that may 
play an important role in these settings where access to conventional MRI is a 
challenge.  
Strengths 
This work has confirmed that in a middle income setting with adequate facilities for 
monitoring, TH can be implemented simply using the available protocols, and should 
be progressively rolled out to where the need is. We have also shown that we have 
the capability to test other neuroprotective therapies in combination with TH. 
These studies are some of the few in LMIC countries that have long term outcome 




Future research in this field should include: 
• Exploration of the mechanism of possible morphine neuroprotection, including 
its influence on cytokines and chemokines. This work is ongoing.  
• Determining the optimal dose of morphine needed for neuroprotection without 
adverse events. 
• Exploring genetic polymorphisms that determine response to morphine. This 
would allow us to offer tailored treatment to patients. 
• Confirming and then exploring the significance and mechanism of lower liver 
dysfunction with TH and morphine co-treatment 
• Multipronged strategies looking at different combinations with TH, eg. EPO (can 
be used later), drugs that can be given to mother when there is evidence of 
fetal compromise eg. allopurinol 
• Exploring the role of NRBC in selecting patients for neuroprotection, particularly 
at referring centres where costly neurophysiological tools are unavaible 
• Validating tools for assessing outcome telephonically such as the Ages and 
Stages Questionnaire Third Edition which has already been validated in a 
South African and Zambian cohort (Hsiao 2016) 
• Comparing BSIDIII scores of these infants with those of a normal local cohort  





Neuroprotective therapies such as therapeutic hypothermia are feasible and 
necessary in LMIC, and do not result in survival with disability, but must be offered 
with adequate monitoring to be safe.  
Cheaper automated devices for TH and brain monitoring should be developed to make 
an impact where the need is greatest.  
Nucleated red blood cells may be useful in selecting patients for TH. 
The routinely used early predictors of outcome have good predictive ability. 
Combining TH with morphine did not improve long-term outcome significantly when 
compared to TH alone, but did improve some early clinical markers of disease. 
Morphine pharmacokinetics in this population were different from what has been 
described in literature, and require further exploration in future studies. 
Long-term follow up studies in these settings are needed, as well as other surrogate 
tools to determine outcome as follow up is usually challenging with high attrition rates.  
There is an urgent need to have the ability to predict outcome at the time of discharge, 
and innovative tools such as mobile low field MRI may play an important role in this 
respect. 
Future work should look at combination therapies with TH while exploring mechanisms 
in which they may act. 
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